83 results on '"Tougeron, David"'
Search Results
2. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
- Author
-
Kerckhove, Nicolas, Tougeron, David, Lepage, Côme, Pezet, Denis, Le Malicot, Karine, Pelkowski, Manon, Pereira, Bruno, and Balayssac, David
- Abstract
Background: The use of oxaliplatin in digestive tract cancers could induce severe peripheral neuropathy (OIPN) decreasing the quality of life of patients and survivors. There is currently, no univocal treatment for these peripheral neuropathies. Donepezil, a reversible inhibitor of cholinesterase, used to treat Alzheimer's disease and dementia, is reported to have a good safety profile in humans, and preclinical data have provided initial evidence of its effectiveness in diminishing neuropathic symptoms and related comorbidities in OIPN animal models.Methods: The DONEPEZOX trial will be a proof-of-concept, randomised, triple-blinded, and multicentre study. It will be the first clinical trial evaluating the efficacy and safety of donepezil for the management of OIPN. Adult cancer survivors with OIPN that report sensory neuropathy according to QLQ-CIPN20 sensory score (equivalence of a grade ≥ 2), at least 6 months after the end of an oxaliplatin-based chemotherapy will be included. Eighty patients will be randomly assigned to receive either donepezil or placebo over 16 weeks of treatment. The primary endpoint will be the rate of responders (neuropathic grade decreases according to the QLQ-CIPN20 sensory score) in the donepezil arm. The severity of OIPN will be assessed by the QLQ-CIPN20 sensory scale before and after 16 weeks of treatment. The comparison versus the placebo arm will be a secondary objective. The other secondary endpoints will be tolerance to donepezil, the severity and features of OIPN in each arm before and after treatment, related-comorbidities and quality of life. Fleming's one-stage design will be used for sample size estimation. This design yields a type I error rate of 0.0417 and power of 91% for a responder rate of at least 30% in donepezil arm. A total of 80 randomized patients is planned.Discussion: This study will allow, in the case of positive results, to initiate a phase 3 randomized and placebo-controlled (primary endpoint) clinical study to assess the therapeutic interest of donepezil to treat OIPN.Trial Registration: NCT05254639 , clincialtrials.gov, Registered 24 February 2022. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Immunothérapie dans les cancers œsogastriques.
- Author
-
Tougeron, David
- Subjects
- *
IMMUNE checkpoint inhibitors , *ESOPHAGEAL tumors , *CLINICAL trials , *SQUAMOUS cell carcinoma , *COMBINATION drug therapy , *CHEMORADIOTHERAPY , *ESOPHAGEAL cancer - Abstract
Résumé: Jusqu'à récemment le traitement des carcinomes épidermoïdes de l'œsophage et des adénocarcinomes œsogastriques avancés HER-2 négatif reposait exclusivement sur la chimiothérapie. Depuis plusieurs années, les inhibiteurs de point de contrôle immunitaire (ICI) sont évalués dans ces cancers d'abord en monothérapie dans les tumeurs chimio-résistantes et plus récemment en combinaison à la chimiothérapie en première ligne de traitement. Dans les tumeurs de l'œsophage, les ICI ont montré une amélioration de la survie globale en monothérapie en deuxième ligne comparée à la chimiothérapie seule, en association avec la chimiothérapie en première ligne comparée à la chimiothérapie seule en cas de score PD-L1 CPS ≥ 10 (Programmed Death Ligand-1 Combined Positive Score) et en situation adjuvante après traitement par radio-chimiothérapie puis chirurgie comparée à la surveillance seule aboutissant donc à trois autorisations de mise sur le marché (AMM) européennes. Concernant les adénocarcinomes gastriques métastatiques avec instabilité micro-satellitaire (dMMR/MSI), les ICI en monothérapie (anti-PD1/PD-L1) et bithérapie (anti-PD1/PD-L1 plus anti-CTLA4) ont montré une efficacité majeure mais le remboursement est toujours en attente en France. Récemment, la combinaison fluoropyrimidine, oxaliplatine et nivolumab (anti-PD-1) a montré sa supériorité sur la chimiothérapie seule en première ligne dans les adénocarcinomes œsogastriques métastatiques avec un CPS ≥ 5 aboutissant également à une AMM européenne. De plus, des essais de phase III en situation péri-opératoire sont en cours, combinant les anti-PD-1/PD-L1 au schéma FLOT. Des essais récents ont montré une efficacité majeure des ICI en situation péri-opératoire des adénocarcinomes œsogastriques dMMR/MSI résécables. Le principal enjeu actuel reste l'identification de biomarqueurs prédictifs d'efficacité au-delà de l'instabilité micro-satellitaire et de l'expression de PD-L1, afin de mieux sélectionner les patients qui ont un gain en survie avec ces différentes combinaisons tout en limitant la toxicité et en préservant la qualité de vie. Until recently, the treatment of esophageal squamous cell carcinoma and HER-2 negative esogastric adenocarcinoma is only based on chemotherapy. Since several years, immune checkpoint inhibitors (ICI) have been evaluated in these cancers, first as monotherapy in chemo-resistant tumors and more recently in combination with chemotherapy as first-line treatment. In esophageal tumors, ICI have shown an improvement of overall survival in second line setting as monotherapy compared to chemotherapy alone, in combination with first line chemotherapy compared to chemotherapy alone in tumours with PD-L1 CPS ≥ 10 (Programmed Death Ligand-1 Combined Positive Score) and in adjuvant setting after treatment by chemoradiotherapy plus surgery compared to placebo, thus resulting in 3 European marketing authorizations. Concerning metastatic gastric adenocarcinomas with micro-satellite instability (dMMR/MSI), ICI in monotherapy (anti-PD1/PD-L1) and doublet (anti-PD1/PD-L1 plus anti-CTLA4) have shown major efficacy but reimbursement is still pending in France. Recently, fluoropyrimidine, oxaliplatin and nivolumab (anti-PD-1) combination showed its superiority over chemotherapy alone in 1st line setting in metastatic esogastric adenocarcinomas with a CPS ≥5 also resulting in a European marketing authorization. In addition, phase III trials in the perioperative setting are ongoing, combining anti-PD-1/PD-L1 with the FLOT regimen. Finally, recent trials have shown major efficacy of ICI in the perioperative setting of resectable dMMR/MSI esogastric adenocarcinoma. The major current challenge remains the identification of predictive biomarkers of ICI efficacy beyond microsatellite instability and PD-L1 expression in order to better select patients who have a survival increase with these different combinations while limiting toxicity and preserving quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).
- Author
-
Tougeron, David, Hentzien, Maxime, Seitz-Polski, Barbara, Bani-Sadr, Firouze, Bourhis, Jean, Ducreux, Michel, Gaujoux, Sébastien, Gorphe, Philippe, Guiu, Boris, Hoang-Xuan, Khê, Huguet, Florence, Lecomte, Thierry, Lièvre, Astrid, Louvet, Christophe, Maggiori, Léon, Mansi, Laura, Mariani, Pascale, Michel, Pierre, Servettaz, Amélie, and Thariat, Juliette
- Subjects
- *
COVID-19 , *IMMUNIZATION , *HEALTH services accessibility , *SPECIALTY hospitals , *CANCER chemotherapy , *CANCER patients , *RISK assessment , *CANCER treatment , *TREATMENT effectiveness , *MESSENGER RNA , *TUMORS , *PALLIATIVE treatment , *PATIENT safety - Abstract
The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only patients with cancer with ongoing treatment or with a treatment having been completed less than 3 years ago but also household and close contacts. High-risk patients with cancer who are candidates for priority access to vaccination are those treated by chemotherapy. The very high-priority population includes patients with curative treatment and palliative first- or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large volume of lung, lymph node and/or haematopoietic tissue. When possible, vaccination should be carried out before cancer treatment begins. SARS-CoV-2 vaccination can be performed during chemotherapy while avoiding periods of neutropenia and lymphopenia. For organisational reasons, vaccination should be performed in cancer care centres with messenger RNA vaccines (or non-replicating adenoviral vaccines in non-immunocompromised patients). Considering the current state of knowledge, the benefit-risk ratio strongly favours SARS-CoV-2 vaccination of all patients with cancer. To obtain more data concerning the safety and effectiveness of vaccines, it is necessary to implement cohorts of vaccinated patients with cancer. • Ultrapriority for severe acute respiratory syndrome coronavirus 2 vaccination is for patients with curative intent treatment. • Priority is for patients with cancer treated with chemotherapy. • Vaccination can be carried out during chemotherapy avoiding periods of bone marrow aplasia. • Contraindications to vaccines if there is an history of allergy to vaccine components. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Cancer colorectal métastatique : prise en charge thérapeutique d'une maladie multi-récidivante.
- Author
-
Randrian, Violaine and Tougeron, David
- Published
- 2021
- Full Text
- View/download PDF
6. Place de la radiothérapie interne sélective dans le traitement des cancers colorectaux métastatiques.
- Author
-
Tougeron, David, Pinaquy, Jean-Baptiste, and Walter, Thomas
- Abstract
Résumé: La radiothérapie interne sélective (RIS) hépatique utilise des microsphères d'Yttrium90 injectées dans l'artère hépatique, qui émettent un rayonnement β et permettent de traiter les métastases hépatiques de cancer colorectal (MHCCR). La RIS se déroule en deux procédures distinctes : un temps préparatoire et la phase de traitement. L'objectif de la dosimétrie personnalisée est d'être le plus tumoricide possible, mais sans risquer l'insuffisance hépato-cellulaire. La tolérance de la RIS est excellente dans la majorité des cas. Selon le TNCD, la RIS est indiquée en situation palliative en cas de maladie hépatique prédominante (≤ 5 lésions extra-hépatiques n'engageant pas le pronostic vital) ; en pratique lorsqu'un traitement par TAS-102 ou régorafenib est discuté. Nous résumons ici la littérature disponible concernant la RIS qui a permis son remboursement, mais aussi les résultats obtenus dans la prise en charge des MHCCR dans des situations plus précoces. Selective internal radiation therapy (SIRT) uses microspheres of 90Yttrium injected into the hepatic artery, which emit β radiation and make it possible to treat liver metastases of colorectal cancer (LMCRC). SIRT is schedulled in two distinct procedures: a work-up and a treatment phase. The goal of personalized dosimetry is to be as tumoricidal as possible and to avoid liver function deficiency. The tolerance of SIRT is excellent in the majority of cases. According to the TNCD, the SIRT is indicated in a palliative situation in patients with LMCRC and a predominant liver disease (≤ 5 non-life-threatening extrahepatic lesions); in practice when treatment with TAS-102 or Regorafenib is discussed. Here, we review the available data concerning the SIRT which allowed its reimbursement, but also the results obtained in the management of MHCCR in earlier treatment lines. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Traitement adjuvant des cancers coliques de stade III : actualités et perspectives.
- Author
-
Randrian, Violaine and Tougeron, David
- Abstract
Résumé: En cas de cancer du côlon avec envahissement ganglionnaire sur la pièce opératoire (stade III), le risque de récidive est supérieur à 50 % à cinq ans en l'absence de traitement adjuvant. Une chimiothérapie adjuvante est donc recommandée et à débuter dans les six semaines après la chirurgie. Le schéma classique associant une fluoropyrimidine (5-fluoro-uracile ou capécitabine) et oxaliplatine (FOLFOX ou XELOX) pendant six mois est recommandé. Le protocole fluoropyrimidine plus oxaliplatine six mois est validé chez les patients de moins de 70 ans avec une tumeur à haut risque de récidive (pT4 et/ou N2). Pour les patients à bas risque de récidive (pT1-3 N1), un protocole XELOX toutes les trois semaines pendant trois mois peut être proposé, réduisant ainsi le taux de neurotoxicité séquellaire sans augmentation cliniquement pertinente du risque de récidive. Les patients de plus de 70 ans constituent une population particulière, hétérogène, et avec moins de données publiées. Une chimiothérapie par 5-fluoro-uracile (schéma LV5FU2) toutes les deux semaines pendant six mois est conseillée chez les patients non aptes à recevoir une bichimiothérapie avec de l'oxaliplatine. De nouveaux critères sont en cours d'évaluation pour déterminer le niveau de risque de récidive, comme des scores immunitaires ou des signatures moléculaires. When a colon cancer with nodal invasion (stage III colon cancer) is diagnosed upon histological examination, the five-year risk of recurrence is over 50%. Adjuvant chemotherapy must start within six weeks after surgery. The standard protocol combining a fluoropyrimidin (5-Fluoro-uracil or capecitabine) with oxaliplatin (FOLFOX or XELOX) every two weeks during six months is recommended. FOLFOX during six months is validated for patients below 70 years old with high risk of recurrence tumour (pT4 and/or N2). For patients with low risk tumours (pT1-3 N1), XELOX protocol every three weeks during three months is an option as it reduces neurotoxicity without increasing the risk of recurrence. Patients over 70 years old form a distinct and heterogenous population for whom few data are available. For unfit patients, a LV5FU2 protocol every two weeks during six months is recommended. New criteria to determine precisely the risk of recurrence, such as immunological scores and molecular signatures, are emerging. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).
- Author
-
Tougeron, David, Emambux, Sheik, Favot, Laure, Lecomte, Thierry, Wierzbicka-Hainaut, Ewa, Samimi, Mahtab, Frouin, Eric, Azzopardi, Nicolas, Chevrier, Jocelyn, Serres, Laura, Godet, Julie, Levillain, Pierre, Paintaud, Gilles, Ferru, Aurélie, Rouleau, Laetitia, Delwail, Adriana, Silvain, Christine, Tasu, Jean-Pierre, Morel, Franck, and Ragot, Stéphanie
- Subjects
- *
THYMIC stromal lymphopoietin , *COLORECTAL cancer , *METASTASIS , *INFLAMMATION , *ANTIMICROBIAL peptides , *ACNEIFORM eruptions - Abstract
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect is a papulopustular acneiform rash. The aim of the CUTACETUX study was to characterize the skin inflammatory response associated with this rash and its relation to treatment efficacy. This prospective study included patients with mCRC treated with first-line chemotherapy plus cetuximab. Patients underwent skin biopsies before the initiation of cetuximab (D0) and before the third infusion (D28), one in a rash zone and one in an unaffected zone. Expression of Th17-related cytokines (IL-17A, IL-21, IL-22), antimicrobial peptides (S100A7 and BD-2), innate response-related cytokines (IL-1β, IL-6, TNF-α and OSM), T-reg-related cytokines (IL-10 and TGF-β), Th1-related cytokine (IFN-γ), Th2-related cytokine (IL-4), Thymic stromal lymphopoietin and keratinocyte-derived cytokines (IL-8, IL-23 and CCL20) were determined by RT-PCR. Twenty-seven patients were included. Levels of most of the cytokines increased at D28 in the rash zone compared to D0. No significant association was observed between variations of cytokines levels and treatment response in the rash zone and only the increase of IL-4 (p =.04) and IL-23 (p =.02) levels between D0 and D28 in the unaffected zone was significantly associated with treatment response. Increased levels of IL-8 (p =.02), BD-2 (p =.02), IL-1β (p =.004) and OSM (p =.02) in the rash zone were associated with longer progression-free survival. Expression of Th2-related and keratinocyte-derived cytokines in the skin was associated with anti-EGFR efficacy. If this inflammatory signature can explain the rash, the exact mechanism by which these cytokines are involved in anti-EGFR tumor response remains to be studied. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Principaux syndromes de prédisposition héréditaires à l'adénocarcinome de l'estomac : orientations diagnostiques et dépistage.
- Author
-
Muller, Marie, Schaefer, Marion, and Tougeron, David
- Subjects
- *
GENETIC counseling , *ADENOCARCINOMA - Abstract
Worldwide, gastric adenocarcinoma is a major public health problem, accounting for 6% of all cancers. In France, the incidence of gastric adenocarcinoma has been stabilized at around 4,700 new cases/year, thanks to better control of risk factors, in particular the eradication of Helicobacter pylori. Around 3% of all cases are hereditary forms of the disease, which are part of cancer predisposition syndromes resulting from the presence of constitutional pathogenic variants in some tumor suppressor genes. The best-known predisposition syndromes that increase the risk of developing gastric adenocarcinoma are hereditary diffuse gastric cancer syndrome (CDH1 and CTNNA1 genes; estimated lifetime risk of around 40%), Lynch syndrome (germline alteration of one of the genes in the Mismatch Repair (MMR) system for repairing DNA mismatches (MLH1, PMS2, MSH2, MSH6); estimated lifetime risk of around 10 %) or certain digestive polyposis (Peutz-Jeghers syndrome linked to STK11, juvenile polyposis linked to SMAD4, GAPPS syndrome linked to APC). Identifying these patients is essential in order to implement preventive strategies and screening for gastric adenocarcinoma in unaffected relatives, as well as to be able to guide treatment strategies in patients with gastric adenocarcinoma (prognostic impact, treatment and risk of second cancer). Screening strategies for gastric adenocarcinoma in these patients include upper gastrointestinal endoscopy, and sometimes lead to discussion of prophylactic surgery, warranting management in an expert centre with a multidisciplinary referral committee. Although these syndromes are rare, the role of oncogenetics in the management of patients at high risk of developing gastric adenocarcinoma (or suffering from this cancer) is crucial, and new predisposition genes are regularly described which may also have therapeutic implications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. La vaccination des patients atteints de cancer solide.
- Author
-
Monier, Anna, Tougeron, David, and Rammaert, Blandine
- Abstract
The immunogenicity of vaccines in patients with cancer under chemotherapy (CT) is poorly understood. However, it has been proven that vaccination reduces the risk of infection, particularly from influenza, hepatitis B and invasive pneumococcal infection. In France, vaccination coverage is low due to lack of patients' and doctors' information (about 30% in patients with cancer for these three vaccines). However, vaccination recommendations exist and are identical regardless of the type of solid tumor (different for hematological diseases). The vaccination schedule should be updated as soon as possible in oncological management. In addition to the general population vaccination schedule, the High Public Health Board recommends vaccination against pneumococcus, hepatitis B virus and influenza ideally 15 days before the start of CT or immunosuppressive targeted therapy (as mTOR inhibitors), and a booster of vaccination against acellular dTP-pertussis and hepatitis B 3 to 6 months after the end of treatment. Live vaccines are contraindicated less than 15 days before CT, during CT and for at least six months after cessation of CT because of the risk of vaccine disease occurrence. For other targeted therapies used as monotherapy (e.g. anti-angiogenic), there is no specific vaccination. There are still no consensual recommendations for patients on immunotherapies given the recent arrival of these treatments. It is thus proposed to update the standard vaccination schedule before treatment, to avoid any vaccination during immunotherapy and live attenuated vaccines remain contraindicated. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
- Author
-
Jeantet, Marion, Tougeron, David, Tachon, Gaelle, Cortes, Ulrich, Archambaut, Céline, Fromont, Gaelle, and Karayan-Tapon, Lucie
- Subjects
- *
COLON cancer , *MONOCLONAL antibodies , *METASTASIS , *TUMORS , *GENETIC mutation - Abstract
Approximately 30% of patients with wild type RAS metastatic colorectal cancer are non-responders to anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs), possibly due to undetected tumoral subclones harboring RAS mutations. The aim of this study was to analyze the distribution of RAS mutations in different areas of the primary tumor, metastatic lymph nodes and distant metastasis. A retrospective cohort of 18 patients with a colorectal cancer (CRC) was included in the study. Multiregion analysis was performed in 60 spatially separated tumor areas according to the pathological tumor node metastasis (pTNM) staging and KRAS, NRAS and BRAF mutations were tested using pyrosequencing. In primary tumors, intra-tumoral heterogeneity for RAS mutation was found in 33% of cases. Inter-tumoral heterogeneity for RAS mutation between primary tumors and metastatic lymph nodes or distant metastasis was found in 36% of cases. Moreover, 28% of tumors had multiple RAS mutated subclones in the same tumor. A high proportion of CRCs presented intra- and/or inter-tumoral heterogeneity, which has relevant clinical implications for anti-EGFR mAbs prescription. These results suggest the need for multiple RAS testing in different parts of the same tumor and/or more sensitive techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
- Author
-
Tougeron, David, Mouillet, Guillaume, Trouilloud, Isabelle, Lecomte, Thierry, Coriat, Romain, Aparicio, Thomas, Des Guetz, Gaetan, Lecaille, Cedric, Artru, Pascal, Sickersen, Gaelle, Cauchin, Estelle, Sefrioui, David, Boussaha, Tarek, Ferru, Aurelie, Matysiak-Budnik, Tamara, Silvain, Christine, Karayan-Tapon, Lucie, Pages, Jean-Christophe, Vernerey, Dewi, and Bonnetain, Franck
- Subjects
- *
ANTINEOPLASTIC agents , *BRAIN tumors , *COLON tumors , *COMBINED modality therapy , *COMPARATIVE studies , *DEGENERATION (Pathology) , *GENETIC disorders , *HETEROCYCLIC compounds , *RESEARCH methodology , *MEDICAL cooperation , *GENETIC mutation , *ORGANOPLATINUM compounds , *RESEARCH , *TUMOR classification , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *KAPLAN-Meier estimator , *HEREDITARY cancer syndromes ,RECTUM tumors - Abstract
Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant chemotherapy while preliminary data suggest chemosensitivity to oxaliplatin. We assessed the efficacy of fluoropyrimidine with and without oxaliplatin in a large cohort of dMMR CC patients.Methods: This retrospective multicenter study included all consecutive patients who underwent curative surgical resection for stage II or III dMMR CC between 2000 and 2011. Prognostic factors were analyzed using Cox models, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. All statistical tests were two-sided.Results: A total of 433 dMMR CC patients were included (56.8% stage II, 43.2% stage III). Mean follow-up was 47.0 months. The patients received surgery alone (n = 263) or surgery plus adjuvant chemotherapy consisting of fluoropyrimidine with (n = 119) or without (n = 51) oxaliplatin. Adjuvant chemotherapy was administered to 16.7% of stage II and 69.0% of stage III CC patients. As compared with surgery alone, adjuvant oxaliplatin-based chemotherapy improved disease-free survival (DFS) in multivariable analysis (HR = 0.35, 95% CI = 0.19 to 0.65, P < .001), contrary to adjuvant fluoropyrimidine alone (HR = 0.73, 95% CI = 0.36 to 1.49, P = .38). In the subgroup analysis, the DFS benefit of oxaliplatin-based chemotherapy was statistically significant in multivariable analysis only in stage III (HR = 0.41, 95% CI = 0.19 to 0.87, P = .02).Conclusion: This study supports the use of adjuvant chemotherapy with fluoropyrimidine plus oxaliplatin in stage III dMMR CC. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
13. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
- Author
-
Maby, Pauline, Tougeron, David, Hamieh, Mohamad, Mlecnik, Bernhard, Kora, Hafid, Bindea, Gabriela, Angell, Helen K., Fredriksen, Tessa, Elie, Nicolas, Fauquembergue, Emilie, Drouet, Aurélie, Leprince, Jérôme, Benichou, Jacques, Mauillon, Jacques, Le Pessot, Florence, Sesboüé, Richard, Tuech, Jean-Jacques, Sabourin, Jean-Christophe, Michel, Pierre, and Frébourg, Thierry
- Subjects
- *
GENETICS of colon cancer , *MICROSATELLITE repeats , *HEREDITARY nonpolyposis colorectal cancer , *IMMUNOTHERAPY , *CLINICAL immunology - Abstract
Colorectal cancers with microsatellite instability (MSI) represent 15% of all colorectal cancers, including Lynch syndrome as the most frequent hereditary form of this disease. Notably, MSI colorectal cancers have a higher density of tumor-infiltrating lymphocytes (TIL) than other colorectal cancers. This feature is thought to reflect the accumulation of frameshift mutations in sequences that are repeated within gene coding regions, thereby leading to the synthesis of neoantigens recognized by CD8+ T cells. However, there has yet to be a clear link established between CD8+ TIL density and frameshift mutations in colorectal cancer. In this study, we examined this link in 103 MSI colorectal cancers from two independent cohorts where frameshift mutations in 19 genes were analyzed and CD3+, CD8+, and FOXP3+ TIL densities were quantitated. We found that CD8+ TIL density correlated positively with the total number of frameshift mutations. TIL densities increased when frameshiftmutations were present within the ASTE1, HNF1A, or TCF7L2 genes, increasing even further when at least one of these frameshift mutations was present in all tumor cells. Through in vitro assays using engineered antigen-presenting cells, we were able to stimulate peripheral cytotoxic T cells obtained from colorectal cancer patients with peptides derived from frameshift mutations found in their tumors. Taken together, our results highlight the importance of a CD8+ T cell immuneresponseagainstMSI colorectal cancer-specificneoantigens, establishing a preclinical rationale to target them as a personalized cellular immunotherapy strategy, an especially appealing goal for patients with Lynch syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells.
- Author
-
Myung Park, Jae, Tougeron, David, Huang, Shengbing, Okamoto, Koichi, and Sinicrope, Frank A.
- Subjects
- *
DNA damage , *CENTROSOMES , *COLON cancer , *RADIATION damage , *NEOPLASTIC cell transformation , *AUTOPHAGY - Abstract
Beclin 1 interacts with UV-irradiation-resistance-associated gene (UVRAG) to form core complexes that induce autophagy. While cells with defective autophagy are prone to genomic instability that contributes to tumorigenesis, it is unknown whether Beclin1 or UVRAG can regulate the DNA damage/repair response to cancer treatment in established tumor cells. We found that siRNA knockdown of Beclin 1 or UVRAG can increase radiation-induced DNA double strand breaks (DSBs), shown by pATM and γH2Ax, and promote colorectal cancer cell death. Furthermore, knockdown of Beclin 1, UVRAG or ATG5 increased the percentage of irradiated cells with nuclear foci expressing 53BP1, a marker of nonhomologous end joining but not RAD51 (homologous recombination), compared to control siRNA. Beclin 1 siRNA was shown to attenuate UVRAG expression. Cells with a UVRAG deletion mutant defective in Beclin 1 binding showed increased radiation-induced DSBs and cell death compared to cells with ectopic wild-type UVRAG. Knockdown of Beclin 1 or UVRAG, but not ATG5, resulted in a significant increase in centrosome number (γ-tubulin staining) in irradiated cells compared to control siRNA. Taken together, these data indicate that Beclin 1 and UVRAG confer protection against radiation-induced DNA DSBs and may maintain centrosome stability in established tumor cells. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
- Author
-
Tougeron, David, Cortes, Ulrich, Ferru, Aurélie, Villalva, Claire, Silvain, Christine, Tourani, Jean Marc, Levillain, Pierre, and Karayan-Tapon, Lucie
- Subjects
- *
ANTINEOPLASTIC agents , *THERAPEUTIC use of monoclonal antibodies , *COLON tumors , *COMBINED modality therapy , *EPIDERMAL growth factor , *LIVER tumors , *METASTASIS , *MONOCLONAL antibodies , *GENETIC mutation , *PROTEINS , *TREATMENT effectiveness , *DISEASE progression ,RECTUM tumors - Abstract
It is now well established that metastatic colorectal cancer patients without KRAS mutation (codon 12) benefit from treatment with an epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb). Recently, EFGR and KRAS mutations have been shown to exist in patients who developed resistance to anti-EGFR mAb. We analyzed KRAS, BRAF V600E and EGFR S492R mutations in 37 post-anti-EGFR mAb tumor samples from 23 patients treated with chemotherapy plus anti-EGFR mAb. No EGFR S492R mutation was detected. A KRAS mutation was found after anti-EGFR mAb in only one tumor. Our results suggest that acquired EGFR S492R and KRAS mutations do not constitute the main mechanism of resistance to anti-EGFR mAb in combination with chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. Epidermal growth factor receptor ( EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
- Author
-
Tougeron, David, Cortes, Ulrich, Ferru, Aurélie, Villalva, Claire, Silvain, Christine, Tourani, Jean, Levillain, Pierre, and Karayan-Tapon, Lucie
- Subjects
- *
COLON cancer patients , *COLON cancer treatment , *EPIDERMAL growth factor receptors , *GENETIC mutation , *CANCER chemotherapy , *MONOCLONAL antibodies , *METASTASIS - Abstract
It is now well established that metastatic colorectal cancer patients without KRAS mutation (codon 12) benefit from treatment with an epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb). Recently, EFGR and KRAS mutations have been shown to exist in patients who developed resistance to anti-EGFR mAb. We analyzed KRAS, BRAF V600E and EGFR S492R mutations in 37 post-anti-EGFR mAb tumor samples from 23 patients treated with chemotherapy plus anti-EGFR mAb. No EGFR S492R mutation was detected. A KRAS mutation was found after anti-EGFR mAb in only one tumor. Our results suggest that acquired EGFR S492R and KRAS mutations do not constitute the main mechanism of resistance to anti-EGFR mAb in combination with chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Regulatory T Lymphocytes Are Associated with Less Aggressive Histologic Features in Microsatellite-Unstable Colorectal Cancers.
- Author
-
Tougeron, David, Maby, Pauline, Elie, Nicolas, Fauquembergue, Émilie, Le Pessot, Florence, Cornic, Marie, Sabourin, Jean-Christophe, Michel, Pierre, Frébourg, Thierry, and Latouche, Jean-Baptiste
- Subjects
- *
COLON cancer , *T cells , *HISTOLOGY , *MICROSATELLITE repeats , *IMMUNOLOGY , *ADENOCARCINOMA , *ONCOLOGY research - Abstract
Background: Colorectal cancers (CRCs) with microsatellite instability (MSI) are associated with a good prognosis and a high density of tumor-infiltrating lymphocytes (TILs). We have undertaken to determine the link between TIL densities and MSI CRC histologic features. Patients and Methods: Using tissue microarrays, T-cell sub-population infiltration, including T cells (CD3), cytotoxic T cells (CD8) and regulatory T cells (FoxP3) were studied in 86 MSI CRCs. We separately analyzed TILs of the stromal and epithelial compartments in the tumor center, the tumoral invasion margin and associated normal tissue. Results: For FoxP3+ TIL density in the tumor center stromal compartment, we found a strong negative correlation with T4 stage (p = 0.01), node invasion (p<0.001) and VELIPI (vascular emboli, lymphatic invasion and perinervous invasion) criteria (p = 0.002). Conclusion: The strong correlation between regulatory T cell density and the absence of VELIPI criteria suggests that this sub-group of T cells is preferentially associated with less invasive tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes.
- Author
-
Tougeron, David, Hamidou, Hadji, Scotté, Michel, Di Fiore, Frédéric, Antonietti, Michel, Paillot, Bernard, and Michel, Pierre
- Subjects
- *
ESOPHAGEAL varices , *DRUG therapy , *RADIOTHERAPY , *METASTASIS , *CANCER treatment - Abstract
Background: Only limited data has been reported so far regarding oesophageal cancer (EC) in elderly patients. The aim of the study is to identify the baseline parameters that influenced therapeutic decision. Methods: All consecutive patients 70 years or older being treated for EC were retrospectively analyzed. Patients without visceral metastasis were divided into two groups: treatment with curative intent (chemoradiotherapy, surgery, radiotherapy, mucosectomy or photodynamic therapy) or best supportive care (BSC). Patients with metastasis were divided into two groups: palliative treatment (chemotherapy, chemoradiotherapy or radiotherapy) or BSC. Results: Two hundred and eighty-two patients were studied. Mean age was 76.5 ± 5.5 years and 22.4% of patients had visceral metastasis. In patients without visceral metastasis (n = 220) the majority had treatment with curative intent (n = 151) whereas in patients with metastasis (n = 62) the majority had BSC (n = 32). Severe adverse events (≥ grade 3) were observed in only 17% of the patients. Patients without specific carcinologic treatment were older, had more weight loss, worse WHO performance status and Charlson score in multivariate analysis. Discussion: Our results suggest that elderly patients with an EC could benefit from cancer treatment without major toxicities. Weight loss, WHO performance status and the Charlson score could be used to select the appropriate treatment in an elderly patient. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.
- Author
-
Tougeron, David, Savoye, Guillaume, Savoye-Collet, Céline, Koning, Edith, Michot, Francis, Lerebours, Eric, and Savoye-Collet, Céline
- Subjects
- *
FISTULA , *HUMAN abnormalities , *ANTI-infective agents , *MEDICAL imaging systems , *CLINICAL medicine , *ANTI-inflammatory agents , *ANTIBIOTICS , *CIPROFLOXACIN , *METHOTREXATE , *METRONIDAZOLE , *THERAPEUTIC use of monoclonal antibodies , *IMMUNOSUPPRESSIVE agents , *AZATHIOPRINE , *COMBINATION drug therapy , *CROHN'S disease , *INTESTINAL fistula , *LONGITUDINAL method , *MAGNETIC resonance imaging , *PREDICTIVE tests , *DISEASE remission , *RETROSPECTIVE studies , *MEDICAL drainage , *THERAPEUTICS - Abstract
Unlabelled: Perianal fistulizing Crohn's disease (PFCD) treatment is based on fistula drainage, antibiotics, immunosuppressant (IS) drugs, and infliximab. Our aim was to study the effectiveness of combination therapy on PFCD and to search for clinical or imaging features associated with the initial complete clinical response and its stability overtime.Patients and Methods: All patients with PFCD treated in our tertiary center between 2000 and 2005 by infliximab in combination with seton placement and/or IS and evaluated by MRI before treatment were included in the study. Basal clinical and MRI characteristics were recorded. Response to treatment was evaluated after the infliximab induction regiment and at the end of the follow-up.Results: Twenty-six patients were included and followed-up for an average 4.9 years. A complex fistula was present in 69% (18/26 patients) of cases and eight (8/26 patients) had an ano-vaginal fistula. After infliximab induction therapy, 13 patients (50%) achieved a complete clinical response. The initial clinical response was significantly associated with the absence of both, active intestinal disease (54% vs. 8%, P = 0.03) and active proctitis (77% vs. 23%, P = 0.01). No initial MRI characteristics were linked to the initial response. In multivariate analysis, only the presence of active proctitis was associated with the lack of response (P = 0.047). At the end of the follow-up, 42% of the patients remained in clinical remission. No clinical characteristics were associated to sustained response when among long-standing responders two exhibited a normal post-treatment MRI.Conclusion: An initial complete response of PFCD was observed in half of the patients after combined therapy including infliximab that decreased to 42% later on. Complete healing of fistulas on MRI was possible but unusual. The initial response seemed related to the absence of active intestinal disease, especially in the rectum, when the long-term response could not be predicted by the basal characteristics of patients. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
20. Small-bowel adenocarcinoma in patient with Crohn's disease: Report of a series of three cases.
- Author
-
Tougeron, David, Lefebure, Benoit, Savoye, Guillaume, Jacques Tuech, Jean, di Fiore, Frederic, and Michel, Pierre
- Subjects
- *
CROHN'S disease , *ADENOCARCINOMA , *CANCER patients , *DIAGNOSIS , *GASTROENTEROLOGISTS - Abstract
Patients affected with Crohn's disease (CD) have a recognized, but low relative risk of developing small-bowel adenocarcinoma (SBA). In fact, SBA develops in 2.2% of patients who have long-standing CD and it is seldom diagnosed preoperatively because of its rarity. A retrospective analysis of all cases of SBA in CD patients since 1980 was carried out in Rouen University Hospital. Three patients with known or unknown CD who presented with SBA with long-term follow-up were analysed. In our first case, the occlusive syndrome revealed SBA and CD simultaneously. Most ileal carcinomas in CD are located in strictures and are often incidentally diagnosed postoperatively, as in our three cases. Digestive surgeons and gastroenterologists must be aware that the diagnosis of SBA in CD is often made fortuitously on histological examination after surgical resection for an occlusive syndrome. Failure to detect SBA in patients with CD results in late diagnosis, with poor survival. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
21. Response to Definitive Chemoradiotherapy and Survival in Patients with an Oesophageal Adenocarcinoma versus Squamous Cell Carcinoma: A Matched-Pair Analysis.
- Author
-
Tougeron, David, Di Fiore, Frédéeric, Hamidou, Hadji, Rigal, Olivier, Paillot, Bernard, and Michel, Pierre
- Subjects
- *
TUMORS , *DRUG therapy , *ESOPHAGEAL cancer , *SQUAMOUS cell carcinoma , *CISPLATIN - Abstract
Objectives: The impact of the histological tumour type in patients treated with definitive chemoradiotherapy (CRT) for an oesophageal cancer is not well established. The aim of this retrospective matched-pair analysis was to evaluate the clinical complete response (CCR) to definitive CRT and the outcome between 2 groups of patients. Methods: Fifty-seven patients with an oesophageal adenocarcinoma (ADC) were matched according to the tumour stage and the WHO performance as well as the CRT regimen status including 57 patients with an oesophageal squamous cell carcinoma (SCC). CRT was based on radiotherapy combined with a cisplatin-based chemotherapy. Results: A CCR was observed in 40 patients (70.2%) with an SCC as compared with 26 patients (45.6%) with an ADC (p = 0.013). SCC patients received significantly more of planned cisplatin and radiotherapy doses than ADC patients (82.0 vs. 67.7%, p = 0.042, and 92.5 vs. 84.5%, p = 0.023, respectively). In responders to CRT, local recurrence was significantly more frequent in SCC patients (52.5 vs. 26.9%, p = 0.046). Median survival in all patients as well as in responders to CRT was not different between the 2 groups. Conclusion: Our study showed that treatment completion and CCR to definitive CRT were more frequent in SCC with, however, more local recurrences in these patients. Further studies are required to confirm this difference in response rate to definitive CRT according to histological type of the tumour in oesophageal cancer. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
22. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
- Author
-
Legoux, Jean-Louis, Faroux, Roger, Barrière, Nicolas, Le Malicot, Karine, Tougeron, David, Lorgis, Véronique, Guerin-Meyer, Véronique, Bourgeois, Vincent, Malka, David, Aparicio, Thomas, Baconnier, Matthieu, Lebrun-Ly, Valérie, Egreteau, Joëlle, Khemissa Akouz, Faïza, Terme, Magali, Lepage, Côme, and Boige, Valérie
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *VASCULAR endothelial growth factors , *DRUG toxicity , *ANTINEOPLASTIC agents , *COLORECTAL cancer , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *METASTASIS , *CYTOTOXINS , *FOLINIC acid , *RESEARCH , *FLUOROURACIL , *DATA analysis software , *PROGRESSION-free survival - Abstract
Simple Summary: In this randomized phase II trial, which included 117 older patients with metastatic colorectal cancer receiving LV5FU2 regimen with or without aflibercept, the primary endpoint was 6-month progression-free survival (PFS). The clinical hypotheses expected a PFS rate at 6 months of over 40% (60% expected). It was 54.7% in both arms (90% CI 42.5–66.5 in both). Given the 6-month PFS, the study can be considered positive. However, the toxicity of aflibercept in this elderly population was high (grade ≥ 3 toxicity in 82% of patients versus 58.2% with LV5FU2 alone), and continuation of the trial into phase III is not envisaged. Fluropyrimidine monotherapy is an option for some patients with inoperable metastatic colorectal cancer. Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this context. The aim of the study was to determine whether aflibercept could increase the efficacy of fluoropyrimidine monotherapy without increasing toxicity. This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in patients unfit to receive doublet cytotoxic chemotherapy. The primary endpoint was 6-month progression-free survival (PFS). The clinical hypotheses expected a PFS rate at 6 months of over 40% (60% expected). A total of 117 patients, with a median age of 81 years, were included: 59 in arm A (LV5FU2-aflibercept) and 58 in arm B (LV5FU2 alone). Six-month PFS was 54.7% in both arms (90% CI 42.5–66.5 in both). Median overall survival was 21.8 months (arm A) and 25.1 months (arm B). Overall toxicity was more common in arm A: grade ≥ 3 toxicity in 82% versus 58.2%. Given the 6-month PFS, the study can be considered positive. However, the toxicity of aflibercept in this population was high, and continuation of the trial into phase III is not envisaged. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort.
- Author
-
Lebeaud, Antoine, Antoun, Leony, Paccard, Jane‐Rose, Edeline, Julien, Bourien, Hélène, Fares, Nadim, Tournigand, Christophe, Lecomte, Thierry, Tougeron, David, Hautefeuille, Vincent, Viénot, Angélique, Henriques, Julie, Williet, Nicolas, Bachet, Jean‐Baptiste, Smolenschi, Cristina, Hollebecque, Antoine, Macarulla, Teresa, Castet, Florian, Malka, David, and Neuzillet, Cindy
- Abstract
Background & Aims Methods Results Conclusions Accumulating data has shown the rising incidence and poor prognosis of early‐onset gastrointestinal cancers, but few data exist on biliary tract cancers (BTC). We aimed to analyse the clinico‐pathological, molecular, therapeutic characteristics and prognosis of patients with early onset BTC (EOBTC, age ≤50 years at diagnosis), versus olders.We analysed patients diagnosed with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma between 1 January 2003 and 30 June 2021. Baseline characteristics and treatment were described in each group and compared. Progression‐free survival, overall survival and disease‐free survival were estimated in each group using the Kaplan‐Meier method.Overall, 1256 patients were included, 188 (15%) with EOBTC. Patients with EOBTC demonstrated fewer comorbidities (63.5% vs. 84.5%, p < .0001), higher tumour stage (cT3–4: 50.0% vs. 32.3%, p = .0162), bilobar liver involvement (47.8% vs. 32.1%, p = .0002), and metastatic disease (67.6% vs. 57.5%, p = .0097) compared to older. Patients with EOBTC received second‐line therapy more frequently (89.5% vs. 81.0% non‐EOBTC, p = .0224). For unresectable patients with BTC, median overall survival was 17.0 vs. 16.2 months (p = .0876), and median progression‐free survival was 5.8 vs. 6.0 months (p = .8293), in EOBTC vs. older. In advanced stages, fewer actionable alterations were found in EOBTC (e.g., IDH1 mutations [7.8% vs. 16.6%]; FGFR2‐fusion [11.7% vs. 8.9%]; p = .029).Patients with EOBTC have a more advanced disease at diagnosis, are treated more heavily at an advanced stage but show similar survival. A distinctive molecular profile enriched for FGRF2 fusions was found. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
- Author
-
Kim, Stefano, Ghiringhelli, Francois, de la Fouchardière, Christelle, Evesque, Ludovic, Smith, Denis, Badet, Nicolas, Samalin, Emmanuelle, Lopez-Trabada Ataz, Daniel, Parzy, Aurelie, Desramé, Jérôme, Baba Hamed, Nabil, Buecher, Bruno, Tougeron, David, Bouché, Olivier, Dahan, Laetitia, Chibaudel, Benoist, El Hajbi, Farid, Mineur, Laurent, Dubreuil, Olivier, and Ben Abdelghani, Meher
- Subjects
- *
ANAL cancer , *ATEZOLIZUMAB , *DOCETAXEL , *CISPLATIN , *FLUOROURACIL , *CASTRATION-resistant prostate cancer - Abstract
The modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen has shown efficacy and safety as first-line treatment for advanced squamous cell carcinoma of the anus, making it a standard regimen. Inhibitors of programmed cell death protein 1 and its ligand, such as pembrolizumab, nivolumab, retifanlimab, avelumab, and atezolizumab, have shown some antitumour activity as monotherapy in advanced squamous cell carcinoma of the anus that is refractory to chemotherapy. This phase 2 study evaluated the combination of mDCF and atezolizumab as first-line treatment in advanced squamous cell carcinoma of the anus. In this randomised, open-label, non-comparative, phase 2 study, participants from 21 centres (academic, private, and community hospitals and cancer research centres) across France with chemo-naive, metastatic, or unresectable locally advanced recurrent squamous cell carcinoma of the anus, aged 18 years or older, and with an Eastern Cooperative Oncology Group performance status of 0 or 1, were randomly allocated (2:1) to receive either atezolizumab (800 mg intravenously every 2 weeks up to 1 year) plus mDCF (eight cycles of 40 mg per m2 docetaxel and 40 mg per m2 cisplatin on day 1 and 1200 mg per m2 per day of fluorouracil for 2 days, every 2 weeks intravenously; group A) or mDCF alone (group B). Randomisation was done centrally using a minimisation technique and was stratified by age (<65 years vs ≥65 years) and disease status. The primary endpoint was investigator-assessed 12-month progression-free survival in the modified intention-to-treat population in group A (35% for the null hypothesis and 50% for the alternative hypothesis). This trial is registered with ClinicalTrials.gov , NCT03519295 , and is closed to new participants. 97 evaluable participants (64 in group A and 33 in group B) were enrolled between July 3, 2018, and Aug 19, 2020. The median follow-up was 26·5 months (95% CI 24·8–28·4). The median age of participants was 64·1 years (IQR 56·2–71·6), and 71 (73%) were female. 12-month progression-free survival was 45% (90% CI 35–55) in group A and 43% (29–58) in group B. In participants with a PD-L1 combined positive score of 5 or greater, 12-month progression-free survival was 70% (95% CI 47–100) in group A and 40% (19–85) in group B (interaction p=0·051) Both groups showed high compliance. Adverse events of grade 3 or higher were observed in 39 (61%) participants in group A and 14 (42%) in group B. The most common grade 3–4 adverse events were neutropenia (nine [14%] participants in group A vs five [15%] in group B), anaemia (nine [14%] vs one [3%]), fatigue (three [5%] vs four [12%]), and diarrhoea (seven [11%] vs one [3%]). Serious adverse events occurred in 16 (25%) participants in group A and four (12%) in group B, and these were mDCF-related in seven (11%) participants in group A and four (12%) in group B. Atezolizumab-related serious adverse events occurred in nine (14%) participants in group A, including grade 2 infusion-related reaction in three (5%), grade 3 infection in two (3%), and grade 2 colitis, grade 3 acute kidney injury, grade 3 sarcoidosis, and a grade 4 platelet count decrease each in one participant (2%). There were no treatment-related deaths. Despite a higher incidence of adverse events, combining atezolizumab with mDCF is feasible, with similar dose intensity in both groups, although the primary efficacy endpoint was not met. The predictive value of a PD-L1 combined positive score of 5 or greater now needs to be confirmed in future studies. GERCOR, Roche. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
- Author
-
Gouriou, Claire, Lemanski, Claire, Pommier, Pascal, Le Malicot, Karine, Saint, Angélique, Rivin del Campo, Eleonor, Evin, Cécile, Quero, Laurent, Regnault, Pauline, Baba-Hamed, Nabil, Ronchin, Philippe, Crehange, Gilles, Tougeron, David, Menager-Tabourel, Elodie, Diaz, Olivia, Hummelsberger, Michael, de la Rocherfordiere, Anne, Drouet, Franck, Vendrely, Véronique, and Lièvre, Astrid
- Abstract
Background: Standard care for non-metastatic squamous cell carcinoma of the anus (SCCA) is chemoradiotherapy, data about elderly patients are scarce. Methods: All consecutive patients treated for non-metastatic SCCA from the French multicenter FFCD-ANABASE cohort were included. Two groups were defined according to age: elderly (≥75 years) and non-elderly (<75). Results: Of 1015 patients, 202 (19.9%) were included in the elderly group; median follow-up was 35.5 months. Among the elderly, there were more women (p = 0.015); frailer patients (p < 0.001), fewer smokers (p < 0.001) and fewer HIV-infected (p < 0.001) than in the non-elderly group. Concomitant chemotherapy and inguinal irradiation were less frequent (p < 0.001 and p = 0.04). In the elderly group; 3-year overall survival (OS), recurrence-free survival (RFS) and colostomy-free survival (CFS) were 82.9%, 72.4% and 78.0%, respectively; complete response rate at 4–6 months was 70.3%. There were no differences between groups for all outcomes and toxicity. In multivariate analyses for the elderly, PS ≥ 2 and locally-advanced tumors were significantly associated with poor OS (HR = 3.4 and HR = 2.80), RFS (HR = 2.4 and HR = 3.1) and CFS (HR = 3.8 and HR = 3.0); and treatment interruption with poor RFS (HR = 1.9). Conclusion: In the FFCD-ANABASE cohort, age did not influence tumor and tolerance outcomes of non-metastatic SCCA. Optimal curative treatment should be offered to elderly patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
- Author
-
Lobet, Sarah, Paintaud, Gilles, Azzopardi, Nicolas, Passot, Christophe, Caulet, Morgane, Chautard, Romain, Desvignes, Céline, Capitain, Olivier, Tougeron, David, Lecomte, Thierry, and Ternant, David
- Subjects
- *
CETUXIMAB , *PROGRESSION-free survival , *COLORECTAL cancer , *METASTASIS , *CANCER patients , *PHARMACOKINETICS - Abstract
Background and Objective: Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The influence of target-antigen on cetuximab pharmacokinetics has never been investigated using target-mediated drug disposition (TMDD) modelling. This study aimed to investigate the relationship between cetuximab concentrations, target kinetics and progression-free survival (PFS). Methods: In this ancillary study (NCT00559741), 91 patients with mCRC treated with cetuximab were assessed. Influence of target levels on cetuximab pharmacokinetics was described using TMDD modelling. The relationship between cetuximab concentrations, target kinetics and time-to-progression (TTP) was described using a joint pharmacokinetic-TTP model, where unbound target levels were assumed to influence hazard of progression by an Emax model. Mitigation strategies of concentration-response relationship, i.e., time-varying endogenous clearance and mutual influences of clearance and time-to-progression were investigated. Results: Cetuximab concentration-time data were satisfactorily described using the TMDD model with quasi-steady-state approximation and time-varying endogenous clearance. Estimated target parameters were baseline target levels (R0 = 43 nM), and complex elimination rate constant (kint = 0.95 day−1). Estimated time-varying clearance parameters were time-invariant component of CL (CL0= 0.38 L/day−1), time-variant component of CL (CL1= 0.058 L/day−1) and first-order rate of CL1 decreasing over time (kdes = 0.049 day−1). Part of concentration-TTP was TTP-driven, where clearance and TTP were inversely correlated. In addition, increased target occupancy was associated with increased TTP. Conclusion: This is the first study describing the complex relationship between cetuximab target-mediated pharmacokinetics and PFS in mCRC patients using a joint PK-time-to-progression model. Further studies are needed to provide a more in-depth description of this relationship. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.
- Author
-
Zwart, Koen, van der Baan, Frederieke H., Cohen, Romain, Aparicio, Thomas, de la Fouchardiére, Christelle, Lecomte, Thierry, Punt, Cornelis J. A., Sefrioui, David, Verheijden, Rik J., Vink, Geraldine R., Wensink, G. Emerens, Zaanan, Aziz, Koopman, Miriam, Tougeron, David, and Roodhart, Jeanine M. L.
- Subjects
- *
COLORECTAL cancer , *HEREDITARY nonpolyposis colorectal cancer , *PROGNOSIS , *METASTASIS , *CANCER chemotherapy , *REGRESSION analysis - Abstract
Background: Current knowledge on prognostic biomarkers (especially BRAFV600E/RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with proficient mismatch repair (pMMR) tumors. It is uncertain whether these biomarkers have the same prognostic value in mCRC patients with deficient mismatch repair (dMMR) tumors. Methods: This observational cohort study combined a population‐based Dutch cohort (2014–2019) and a large French multicenter cohort (2007–2017). All mCRC patients with a histologically proven dMMR tumor were included. Results: In our real‐world data cohort of 707 dMMR mCRC patients, 438 patients were treated with first‐line palliative systemic chemotherapy. Mean age of first‐line treated patients was 61.9 years, 49% were male, and 40% had Lynch syndrome. BRAFV600E mutation was present in 47% of tumors and 30% harbored a RAS mutation. Multivariable regression analysis on OS showed significant hazard rates (HR) for known prognostic factors as age and performance status, however showed no significance for Lynch syndrome (HR: 1.07, 95% CI: 0.66–1.72), BRAFV600E mutational status (HR: 1.02, 95% CI: 0.67–1.54), and RAS mutational status (HR: 1.01, 95% CI: 0.64–1.59), with similar results for PFS. Conclusion: BRAFV600E and RAS mutational status are not associated with prognosis in dMMR mCRC patients, in contrast to pMMR mCRC patients. Lynch syndrome is also not an independent prognostic factor for survival. These findings underline that prognostic factors of patients with dMMR mCRC are different of those with pMMR, which could be taken into consideration when prognosis is used for clinical decision‐making in dMMR mCRC patients and underline the complex heterogeneity of mCRC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. ABCB4/MDR3 gene mutations and cholangiocarcinomas
- Author
-
Tougeron, David, Fotsing, Ginette, Barbu, Veronique, and Beauchant, Michel
- Published
- 2012
- Full Text
- View/download PDF
29. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study.
- Author
-
Bergen, Elisabeth S., Pilla, Lorenzo, Auclin, Edouard, Ilhan-Mutlu, Aysegül, Prager, Gerald W., Pietrantonio, Filippo, Antista, Maria, Ghelardi, Filippo, Basile, Debora, Aprile, Giuseppe, Longarini, Raffaella, Hautefeuille, Vincent, Tougeron, David, Artru, Pascal, Mabro, May, Drouillard, Antoine, Roth, Gael, Ben Abdelghani, Meher, Clement, Inès, and Toullec, Clemence
- Subjects
- *
INDUCTION chemotherapy , *ADENOCARCINOMA , *PROGRESSION-free survival , *MULTIVARIATE analysis , *TRASTUZUMAB - Abstract
Background: The optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma (OGA) remains challenging. Methods: Patients treated with trastuzumab (T) plus platinum salts and fluoropyrimidine (F) as first-line chemotherapy between 2010 and 2020 for HER2-positive advanced OGA at 17 academic care centers in France, Italy, and Austria were included. The primary objective was the comparison of F + T vs T alone as maintenance regimen in terms of progression-free survival (PFS) and overall survival (OS) after a platinum-based chemotherapy induction + T. As secondary objective, PFS and OS between patients treated with reintroduction of initial chemotherapy or standard second-line chemotherapy at progression were assessed. Results: Among the 157 patients included, 86 (55%) received F + T and 71 (45%) T alone as a maintenance regimen after a median of 4 months of induction chemotherapy. Median PFS from start of maintenance therapy was 5.1 months in both groups (95% CI 4.2–7.7 for F + T and 95% CI 3.7–7.5 for T alone; p = 0.60) and median OS was 15.2 (95% CI 10.9–19.1) and 17.0 months (95% CI 15.5–21.6) for F + T and T alone, respectively (p = 0.40). Of 112/157 patients (71%) receiving systemic therapy after progression under maintenance, 26/112 (23%) were treated with a reintroduction of initial chemotherapy + T and 86/112 (77%) with a standard second-line regimen. Here, median OS was significantly longer with the reintroduction (13.8 (95% CI 12.1–19.9) vs 9.0 months (95% CI 7.1–11.9); p = 0.007) as confirmed by multivariate analysis (HR 0.49; 95% CI 0.28–0.85; p = 0.01). Conclusion: No additional benefit of adding F to T monotherapy as a maintenance treatment could be observed. Reintroduction of initial therapy at first progression may be a feasible approach to preserve later treatment lines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Atrophic Gastritis and Autoimmunity: Results from a Prospective, Multicenter Study.
- Author
-
Osmola, Malgorzata, Hemont, Caroline, Chapelle, Nicolas, Vibet, Marie-Anne, Tougeron, David, Moussata, Driffa, Lamarque, Dominique, Bigot-Corbel, Edith, Masson, Damien, Blin, Justine, Leroy, Maxime, Josien, Regis, Mosnier, Jean-François, Martin, Jérôme, and Matysiak-Budnik, Tamara
- Subjects
- *
ATROPHIC gastritis , *ANTINUCLEAR factors , *AUTOIMMUNITY , *AUTOIMMUNE diseases , *HELICOBACTER pylori , *MYOSITIS , *PRECANCEROUS conditions - Abstract
Despite a global decrease, gastric cancer (GC) incidence appears to be increasing recently in young, particularly female, patients. The causal mechanism for this "new" type of GC is unknown, but a role for autoimmunity is suggested. A cascade of gastric precancerous lesions, beginning with chronic atrophic gastritis (CAG), precedes GC. To test the possible existence of autoimmunity in patients with CAG, we aimed to analyze the prevalence of several autoantibodies in patients with CAG as compared to control patients. Sera of 355 patients included in our previous prospective, multicenter study were tested for 19 autoantibodies (anti-nuclear antibodies, ANA, anti-parietal cell antibody, APCA, anti-intrinsic factor antibody, AIFA, and 16 myositis-associated antibodies). The results were compared between CAG patients (n = 154), including autoimmune gastritis patients (AIG, n = 45), non-autoimmune gastritis patients (NAIG, n = 109), and control patients (n = 201). ANA positivity was significantly higher in AIG than in NAIG or control patients (46.7%, 29%, and 27%, respectively, p = 0.04). Female gender was positively associated with ANA positivity (OR 0.51 (0.31–0.81), p = 0.005), while age and H. pylori infection status were not. Myositis-associated antibodies were found in 8.9% of AIG, 5.5% of NAIG, and 4.4% of control patients, without significant differences among the groups (p = 0.8). Higher APCA and AIFA positivity was confirmed in AIG, and was not associated with H. pylori infection, age, or gender in the multivariate analysis. ANA antibodies are significantly more prevalent in AIG than in control patients, but the clinical significance of this finding remains to be established. H. pylori infection does not affect autoantibody seropositivity (ANA, APCA, AIFA). The positivity of myositis-associated antibodies is not increased in patients with CAG as compared to control patients. Overall, our results do not support an overrepresentation of common autoantibodies in patients with CAG. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Th‐17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of Helicobacter pylori‐infected patients independently of their clinical outcomes.
- Author
-
Cremniter, Julie, Bodet, Charles, Tougeron, David, Dray, Xavier, Guilhot, Joëlle, Jégou, Jean‐François, Morel, Franck, Lecron, Jean‐Claude, Silvain, Christine, and Burucoa, Christophe
- Subjects
- *
HELICOBACTER pylori , *HELICOBACTER pylori infections , *GRAM-negative bacteria , *HELICOBACTER , *PEPTIC ulcer - Abstract
Abstract: Background: The pathological determinism of H. pylori infection is explained by complex interplay between bacterial virulence and host inflammatory response. In a large prospective multicenter clinical study, Th17 response, expression of antimicrobial peptides (AMPs), cagA and vacA status, and bacterial density were investigated in the gastric mucosa of H. pylori ‐infected patients. Materials and methods: Gastric inflammatory response was analyzed by RT‐qPCR for quantification of Th17 cytokines (IL‐17A, IL‐22), CXCL‐8, and AMPs (BD2 and S100A9) mRNA levels in gastric biopsies. Detection and genotyping of H. pylori strains were achieved by bacterial culture and PCR. Results: Among 787 patients screened for H. pylori, 269 were analyzed (147 H. pylori ‐infected and 122 uninfected patients). In H. pylori ‐infected patients, distribution was 83 gastritis, 12 duodenal ulcers, 5 gastric ulcers, and 47 precancerous and cancerous lesions. CXCL‐8, IL‐17A, BD2, and S100A9 mRNA levels were significantly increased in H. pylori ‐infected patients but, surprisingly, IL‐22 was not, and no difference was shown between H. pylori ‐related diseases. A positive correlation was identified between S100A9 expression and bacterial density. Although expression of the virulence genes cagA and vacA did not impact inflammatory response, patients infected with a cagA‐positive strain were associated with severe H. pylori ‐related diseases. Conclusion: This study showed that CXCL‐8, IL‐17A, and AMPs are not differently expressed according to the various H. pylori ‐related diseases. The clinical outcome determinism of H. pylori infection is most likely not driven by gastric inflammation but rather tends to mainly influenced by bacterial virulence factors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
- Author
-
Salimon, Maëva, Prieux-Klotz, Caroline, Tougeron, David, Hautefeuille, Vincent, Caulet, Morgane, Gournay, Jérôme, Matysiak-Budnik, Tamara, Bennouna, Jaafar, Tiako Meyo, Manuela, Lecomte, Thierry, Zaanan, Aziz, Touchefeu, Yann, Salimon, Maëva, and Gournay, Jérôme
- Subjects
- *
ANTINEOPLASTIC agents , *BILIRUBIN , *CANCER cells , *CISPLATIN , *COMPARATIVE studies , *HEPATOCELLULAR carcinoma , *LIVER tumors , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SURVIVAL , *VIRAL antibodies , *CHOLANGIOCARCINOMA , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DISEASE progression , *DEOXYCYTIDINE - Abstract
Background: Hepatocholangiocarcinoma (cHCC-ICC) is a rare liver tumour for which no data on chemosensitivity exist. The aims of this multicentre study were to evaluate overall survival (OS), progression-free survival (PFS), and prognostic factors in cHCC-ICC treated by gemcitabine plus platinum as first-line.Methods: Unresectable cHCC-ICC treated by gemcitabine plus platinum-based chemotherapy between 2008 and 2017 were retrospectively analysed. Diagnosis was based on histology or, in case of ICC or HCC histology, on discordant computerised tomography scan enhancement patterns associated with discordant serum tumour marker elevation suggesting the alternative tumour. OS and PFS were evaluated by Kaplan-Meier method and prognostic factors by Log-rank test and Cox model.Results: Among 30 patients included, cHCC-ICC was histologically proven in 22 (73.3%). 18 (60%) received gemcitabine plus oxaliplatin (GEMOX), 9 (30%) GEMOX plus bevacizumab, and 3 (10%) gemcitabine plus cisplatin. RECIST criteria were reported in 28 patients: 8 (28.6%) showed partial response, 14 (50%) stable disease, and 6 (21.4%) tumour progression at first evaluation. Median PFS and OS were 9.0 and 16.2 months, respectively. Serum bilirubin ⩾30 μmol l-1 (P=0.001) and positive serology for HBV and/or HCV (P=0.014) were independent poor prognostic factors for OS.Conclusions: Gemcitabine plus platinum-based chemotherapy is effective as first-line for advanced cHCC-ICC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
33. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
- Author
-
Lepage, Côme, Phelip, Jean-Marc, Lievre, Astrid, Le-Malicot, Karine, Dahan, Laetitia, Tougeron, David, Toumpanakis, Christos, Di-Fiore, Frédéric, Lombard-Bohas, Catherine, Borbath, Ivan, Coriat, Romain, Lecomte, Thierry, Guimbaud, Rosine, Petorin, Caroline, Legoux, Jean-Louis, Michel, Pierre, Scoazec, Jean-Yves, Smith, Denis, and Walter, Thomas
- Subjects
- *
PANCREATIC tumors , *DUODENAL tumors , *CONFIDENCE intervals , *RANDOMIZED controlled trials , *NEUROENDOCRINE tumors , *SOMATOSTATIN , *BLIND experiment , *DESCRIPTIVE statistics , *STATISTICAL sampling , *PROGRESSION-free survival - Abstract
Following European guidelines, patients with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumours (NETs) should receive systemic combination chemotherapy until progression. Aggressive disease is defined as progressive and/or symptomatic metastases with or without significant hepatic invasion (>30–50%), and/or bone metastases. This academic randomised, double-blind, placebo-controlled phase II study aims to evaluate lanreotide autogel 120 mg (LAN) as maintenance treatment after at least 2 months of first-line treatment (L1) in aggressive G1-G2 DP-NET. Patients were randomly assigned in a 1:1 ratio to receive LAN or placebo (PBO), every 28 days, until progression or toxicity. The primary end-point was progression-free survival (PFS) at 6 months. Among the 118 planned patients, 53 were included. Of these, 81.1% had a G2 tumour, and 90.6% had metastatic disease. L1 therapy consisted of chemotherapy (96.8%). Median duration of L1 was 4.6 months (range: 2.0–7.7). At the time of randomisation, 81.1% of patients had stable disease. Median follow-up was 27.0 months (95% CI: 19.5; 31.2). PFS at 6 months was 73.1% (90% CI: 55.3; 86.6) in LAN versus 54.2% (90% CI: 35.8; 71.8) in PBO. Median PFS was 19.4 months (95% CI: 7.6; 32.6) and 7.6 months (95% CI: 3.0; 9.0), respectively. Median overall survival was 41.9 months in PBO and was not reached in LAN. The toxicity profile was mainly grade 1–2 expected toxicities. The encouraging results of lanreotide autogel 120 mg as a maintenance treatment after L1 in aggressive G1/2 DP-NET should be confirmed. NCT02288377 (clinicaltrials.gov). • Duodeno-pancreatic NETs first-line treatment includes chemotherapy or targeted therapy. • First induction anti-tumour treatment often leads to long periods of non-progression. • This is the first study designed to evaluate a maintenance strategy in this situation. • A maintenance therapy using lanreotide 120 mg LP is feasible. • It appears to increase PFS without inducing excess toxicity or impairing quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
- Author
-
Taieb, Julien, Svrcek, Magali, Cohen, Romain, Basile, Debora, Tougeron, David, and Phelip, Jean-Marc
- Subjects
- *
DIAGNOSIS of hereditary nonpolyposis colorectal cancer , *GENETIC mutation , *IMMUNE checkpoint inhibitors , *CARCINOGENESIS , *HEREDITARY nonpolyposis colorectal cancer , *EARLY detection of cancer , *METASTASIS , *CANCER relapse , *METABOLIC disorders , *DNA repair , *PHENOTYPES , *DRUG resistance in cancer cells , *IMMUNOTHERAPY - Abstract
Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair (MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic setting. Nearly 30% of MSI CRCs occur in a context of constitutional mutation of the MMR system (Lynch syndrome). Others are sporadic cancers linked to a hypermethylation of the MLH-1 promoter. The pathogenic alterations of MMR genes lead to the accumulation of frequent somatic mutational events and these tumours arbour a high antigen burden and are highly infiltrated with cytotoxic T-cell lymphocytes. Microsatellite instability/DNA mismatch repair deficiency (MSI/dMMR) status has prognostic and predictive implications in non-metastatic and metastatic CRCs. The prognostic value of MSI status in non-metastatic CRCs has been studied extensively, yet the data are more limited for its predictive value in terms of adjuvant chemotherapy efficacy. In both cases (metastatic and non-metastatic settings) treatment with immune check-point inhibitors (ICIs) have shown a remarkable effectiveness in the context of MSI/dMMR status. Indeed, recent data from prospective cohorts and randomised trials have shown a dramatical improvement of survival with immunotherapy (programmed death-ligand 1 [PD-(L)1] cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] blockage) in metastatic or non-metastatic MSI/dMMR CRC. In this review we report and discuss how and for whom to test for the MSI/dMMR phenotype, as well as the prognostic value of this phenotype and the new treatment recommendations options for this unique CRC population. Despite their efficacy, primary and secondary resistance to immune checkpoint inhibitors (ICIs) are observed in more than 50% MSI-H/dMMR CRC patients and in the future how to identify these patients and to overcome resistance will be an important challenge. • Microsatellite unstable (MSI) status has to be tested in all colorectal cancer (CRC) stages for Lynch syndrome screening. • MSI patients represent 10–20% of localised and 5% of metastatic CRCs. • Localised MSI CRCs have a better prognosis than localised microsatellite stable (MSS) CRCs. • Immunotherapy is very efficient in most MSI CRCs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
- Author
-
Portal, Alix, Pernot, Simon, Tougeron, David, Arbaud, Claire, Bidault, Anne Thirot, de la Fouchardière, Christelle, Hammel, Pascal, Lecomte, Thierry, Dréanic, Johann, Coriat, Romain, Bachet, Jean-Baptiste, Dubreuil, Olivier, Marthey, Lysiane, Dahan, Laetitia, Tchoundjeu, Belinda, Locher, Christophe, Lepère, Céline, Bonnetain, Franck, Taieb, Julien, and de la Fouchardière, Christelle
- Subjects
- *
THERAPEUTIC use of antimetabolites , *ADENOCARCINOMA , *ANTINEOPLASTIC agents , *CLINICAL trials , *LONGITUDINAL method , *METASTASIS , *PANCREATIC tumors , *PACLITAXEL , *SURVIVAL analysis (Biometry) , *ALBUMINS , *TREATMENT effectiveness , *DEOXYCYTIDINE - Abstract
Background: There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free survival is consistently <4 months in this setting. The aim of this study was to evaluate the efficacy and tolerability of Nab-paclitaxel plus gemcitabine (A+G) after Folfirinox failure in MPA.Methods: From February 2013 to July 2014, all consecutive patients treated with A+G for histologically proven MPA after Folfirinox failure were prospectively enrolled in 12 French centres. A+G was delivered as described in the MPACT trial, until disease progression, patient refusal or unacceptable toxicity.Results: Fifty-seven patients were treated with Nab-paclitaxel plus gemcitabine, for a median of 4 cycles (range 1-12). The disease control rate was 58%, with a 17.5% objective response rate. Median overall survival (OS) was 8.8 months (95% CI: 6.2-9.7) and median progression-free survival was 5.1 months (95% CI: 3.2-6.2). Since the start of first-line chemotherapy, median OS was 18 months (95% CI: 16-21). No toxic deaths occurred. Grade 3-4 toxicities were reported in 40% of patients, consisting of neutropenia (12.5%), neurotoxicity (12.5%), asthenia (9%) and thrombocytopenia (6.5%).Conclusions: A+G seems to be effective, with a manageable toxicity profile, after Folfirinox failure in patients with MPA. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
36. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
- Author
-
Zaibet, Sonia, Hautefeuille, Vincent, Auclin, Edouard, Lièvre, Astrid, Tougeron, David, Sarabi, Mathieu, Gilabert, Marine, Wasselin, Julie, Edeline, Julien, Artru, Pascal, Bechade, Dominique, Morin, Clémence, Ducoulombier, Agnes, Taieb, Julien, and Pernot, Simon
- Subjects
- *
ADENOCARCINOMA , *PANCREATIC tumors , *FOLINIC acid , *ALBUMINS , *RESEARCH , *RETROSPECTIVE studies , *ANTINEOPLASTIC agents , *DEOXYCYTIDINE , *FLUOROURACIL , *PACLITAXEL - Abstract
Background: Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist. This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for mPA after FFX failure.Methods: In this retrospective real-world multicenter study, from 2011 to 2019, patients with mPA receiving Gem-Nab (Gem 1000 mg/m² + Nab 125 mg/m², 3 out of 4 weeks) or Gem alone were included after progression on FFX.Results: A total of 427 patients were included. Patients receiving Gem-Nab had more metastatic sites, peritoneal disease and less PS 2 (24% vs. 35%). After median follow-up of 22 months, Gem-Nab was associated with better disease control rate (DCR) (56% vs. 32%; P < 0.001), progression-free survival (PFS) (3.5 vs. 2.3 months; 95% CI: 0.43-0.65) and overall survival (OS) (7.1 vs. 4.7 months; 95% CI: 0.53-0.86). After multivariate analysis, Gem-Nab and PS 0/1 were associated with better OS and PFS. Grade 3/4 toxicity was more frequent with Gem-Nab (44% vs. 29%).Conclusion: In this study, Gem-Nab was associated with better DCR, PFS and OS compared with Gem alone in patients with mPA after FFX failure, at the cost of higher toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
37. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
- Author
-
Hafliger, Emilie, Boccaccino, Alessandra, Lapeyre-Prost, Alexandra, Perret, Audrey, Gallois, Claire, Antista, Maria, Pilla, Lorenzo, Lecomte, Thierry, Scartozzi, Mario, Soularue, Emilie, Salvatore, Lisa, Bourgeois, Vincent, Salati, Massimiliano, Tougeron, David, Evesque, Ludovic, Vaillant, Jean-Nicolas, El-Khoury, Reem, Lonardi, Sara, Cremolini, Chiara, and Taieb, Julien
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *GENETIC mutation , *CONFIDENCE intervals , *PROTEIN kinase inhibitors , *EPIDERMAL growth factor receptors , *METASTASIS , *ANTINEOPLASTIC agents , *RETROSPECTIVE studies , *COLORECTAL cancer , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *PROGRESSION-free survival - Abstract
Encorafenib plus cetuximab is efficient in anti-EGFR-naïve patients with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). No data are available concerning the efficacy of BRAF inhibitors associated with anti-EGFRs (B + E) in patients previously treated with an anti-EGFR agent. We retrospectively collected a series of patients with BRAFm mCRC treated with B + E after previous anti-EGFR treatment, in 14 centers. Progression-free survival (PFS) and overall survival (OS) were calculated from the start of treatment, and we reported objective response and disease control rates (ORR, DCR; RECIST V1.1). Twenty-five BRAFm mCRC patients were enrolled. Prior to B + E treatment, 4/10/11 patients were treated with 1/2/> 2 previous treatment lines. Ten patients received previous panitumumab, 14 cetuximab, 1 both. Immediate progression with previous anti-EGFR was reported for 7 patients. Anti-BRAF was encorafenib for 21 patients, dabrafenib for 4 patients, with cetuximab for 24 patients and panitumumab for 1 patient. ORR was 40% (10 patients) and DCR was 80% (20 patients). Median PFS and OS were 4.8 months (95% CI, 4.01–7.95) and 10.1 months (95% CI, 7.75-NR). DCR amongst patients with previous primary resistance to anti-EGFR (N = 7) was 100%. Two patients discontinued B + E due to drug-related adverse event. Though in a limited retrospective series of patients, these results show the efficacy of the combination of anti-BRAF and anti-EGFRs in BRAFm mCRC patients previously treated with an anti-EGFR. The use of this combination should thus not be ruled out in this population with limited therapeutic options. • Series of 25 non anti-EGFR-naïve patients treated by anti-BRAF + anti-EGFR for a colorectal cancer. • Median progression free survival and overall survival were 4.8 and 10.1 months. • Ten out of 24 patients had an objective response rate. • These results are very close to those reported in BEACON trial. • This proves the efficacy of encorafenib + cetuximab in non-naïve anti-EGFR patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).
- Author
-
Brugel, Mathias, Letrillart, Léa, Evrard, Camille, Thierry, Aurore, Tougeron, David, El Amrani, Mehdi, Piessen, Guillaume, Truant, Stéphanie, Turpin, Anthony, d'Engremont, Christelle, Roth, Gaël, Hautefeuille, Vincent, Regimbeau, Jean M., Williet, Nicolas, Schwarz, Lilian, Di Fiore, Frédéric, Borg, Christophe, Doussot, Alexandre, Lambert, Aurélien, and Moulin, Valérie
- Subjects
- *
ADENOCARCINOMA , *PANCREATIC tumors , *RESEARCH , *SCIENTIFIC observation , *CANCER chemotherapy , *TUMOR classification , *STAY-at-home orders , *COMBINED modality therapy , *COVID-19 pandemic , *LONGITUDINAL method - Abstract
The COVID-19 pandemic caused major oncology care pathway disruption. The CAPANCOVID study aimed to evaluate the impact on pancreatic adenocarcinoma (PA) – from diagnosis to treatment – of the reorganisation of the health care system during the first lockdown. This multicentre ambispective observational study included 833 patients diagnosed with PA between September 1, 2019 and October 31, 2020 from 13 French centres. Data were compared over three periods defined as before the outbreak of COVID-19, during the first lockdown (March 1 to May 11, 2020) and after lockdown. During the lockdown, mean weekly number of new cases decreased compared with that of pre-pandemic levels (13.2 vs. 10.8, −18.2%; p = 0.63) without rebound in the post-lockdown period (13.2 vs. 12.9, −1.7%; p = 0.97). The number of borderline tumours increased (13.6%–21.7%), whereas the rate of metastatic diseases rate dropped (47.1%–40.3%) (p = 0.046). Time-to-diagnosis and -treatment were not different over periods. Waiting neoadjuvant chemotherapy in resectable tumours was significantly favoured (24.7%–32.6%) compared with upfront surgery (13%–7.8%) (p = 0.013). The use of mFOLFIRINOX preoperative chemotherapy regimen decreased (84.9%–69%; p = 0.044). After lockdown, the number of borderline tumours decreased (21.7%–9.6%) and advanced diseases increased (59.7%–69.8%) (p = 0.046). SARS-CoV-2 infected 39 patients (4.7%) causing 5 deaths (12.8%). This cohort study suggests the existence of missing diagnoses and of a shift in disease stage at diagnosis from resectable to advanced diseases with related therapeutic modifications whose prognostic consequences will be known after the planned follow-up. Clinicaltrials.gov NCT04406571. • A total of 833 patients with pancreatic adenocarcinoma were analysed. • During the lockdown, the weekly number of new cases decreased by 18.2%. • Neoadjuvant chemotherapy was favoured compared with upfront surgery (p = 0.013). • Disease stage shifted from localised to advanced disease (p = 0.046). • SARS-CoV-2 infected 39 patients (4.7%) causing 5 deaths (12.8%). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma.
- Author
-
Hilmi, Marc, Neuzillet, Cindy, Lefèvre, Jérémie H., Svrcek, Magali, Vacher, Sophie, Benhaim, Leonor, Dartigues, Peggy, Samalin, Emmanuelle, Lazartigues, Julien, Emile, Jean-François, Rigault, Eugénie, Rioux-Leclercq, Nathalie, de La Fouchardière, Christelle, Tougeron, David, Cacheux, Wulfran, Mariani, Pascale, Courtois, Laura, Delaye, Matthieu, Dangles-Marie, Virginie, and Lièvre, Astrid
- Subjects
- *
RESEARCH , *GRAM-negative bacteria , *RETROSPECTIVE studies , *SURGERY , *PATIENTS , *ANAL tumors , *TREATMENT effectiveness , *CANCER patients , *BACTERIAL growth , *MICROBIOLOGICAL techniques , *DESCRIPTIVE statistics , *TUMOR markers , *PROGRESSION-free survival , *POLYMERASE chain reaction , *SQUAMOUS cell carcinoma , *LONGITUDINAL method , *PROPORTIONAL hazards models , *EVALUATION - Abstract
Simple Summary: The main prognostic factors of localized/locally advanced anal squamous cell carcinoma (ASCC) are insufficient to predict 10–20% of metastatic relapses. Fusobacterium nucleatum is among the most studied bacteria in digestive tract cancers and has been described as a poor prognostic factor in several digestive cancers. We retrospectively analyzed surgical samples from a homogeneous multicenter cohort of 166 patients with ASCC who underwent abdominoperineal resection. This study showed that F. nucleatum was an independent predictor of favorable overall survival and disease-free survival. This allowed the identification of a patient subgroup with a good prognosis (upper tercile). Our current work strengthens the new insight into the prognostic role of intratumoral F. nucleatum in cancer patients. Validation of these findings would allow to guide therapeutic strategies in dedicated trials by proposing intensification or de-escalation of systemic treatments and follow-up according to F. nucleatum loads. Main prognostic factors of anal squamous cell carcinoma (ASCC) are tumor size, differentiation, lymph node involvement, and male gender. However, they are insufficient to predict relapses after exclusive radiotherapy (RT) or chemoradiotherapy (CRT). Fusobacterium nucleatum has been associated with poor prognosis in several digestive cancers. In this study, we assessed the association between intratumoral F. nucleatum load and clinico-pathological features, relapse, and survival in patients with ASCC who underwent abdominoperineal resection (APR) after RT/CRT. We retrospectively analyzed surgical samples from a cohort of 166 patients with ASCC who underwent APR. F. nucleatum 16S rRNA gene sequences were quantified using real-time quantitative PCR. We associated F. nucleatum load with classical clinicopathological features, overall survival (OS), disease-free survival (DFS), and metastasis-free survival (MFS) using Cox regression univariate and multivariate analyses. Tumors harboring high loads of F. nucleatum (highest tercile) showed longer OS and DFS (median: not reached vs. 50.1 months, p = 0.01, and median: not reached vs. 18.3 months, p = 0.007, respectively). High F. nucleatum load was a predictor of longer OS (HR = 0.55, p = 0.04) and DFS (HR = 0.50, p = 0.02) in multivariate analysis. High F. nucleatum load is an independent favorable prognostic factor in patients with ASCC who underwent APR. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study.
- Author
-
Chapelle, Nicolas, Osmola, Malgorzata, Martin, Jérôme, Blin, Justine, Leroy, Maxime, Jirka, Iva, Moussata, Driffa, Lamarque, Dominique, Olivier, Raphael, Tougeron, David, Hay-Lombardie, Anne, Bigot-Corbel, Edith, Masson, Damien, Mosnier, Jean-François, and Matysiak-Budnik, Tamara
- Subjects
- *
ENZYME-linked immunosorbent assay , *FERRITIN , *BIOMARKERS , *DIAGNOSIS , *PEPSINOGEN , *DISEASE risk factors , *ATROPHIC gastritis - Abstract
Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), a gastric precancerous lesion, is of growing interest for identification of patients at increased risk of gastric cancer. The aim was to analyze the diagnostic performance of serum pepsinogen testing using another method, chemiluminescent enzyme immunoassay (CLEIA), as well as of other new potential biomarkers. Material and Methods: The sera of patients considered at increased risk of gastric cancer and undergoing upper endoscopy collected in our previous prospective, multicenter study were tested for pepsinogen I (PGI) and II (PGII), interleukin-6 (IL-6), human epididymal protein 4 (HE-4), adiponectin, ferritin and Krebs von den Lungen (KL-6) using the CLEIA. The diagnostic performance for the detection of AG was calculated by taking histology as the reference. Results: In total, 356 patients (162 men (46%); mean age 58.6 (±14.2) years), including 152 with AG, were included. For the detection of moderate to severe corpus AG, sensitivity and specificity of the pepsinogen I/II ratio were of 75.0% (95%CI 57.8–87.9) and 92.6% (88.2–95.8), respectively. For the detection of moderate to severe antrum AG, sensitivity of IL-6 was of 72.2% (95%CI 46.5–90.3). Combination of pepsinogen I/II ratio or HE-4 showed a sensitivity of 85.2% (95%CI 72.9–93.4) for the detection of moderate to severe AG at any location. Conclusion: This study shows that PG testing by CLEIA represents an accurate assay for the detection of corpus AG. Additionally, IL-6 and HE-4 may be of interest for the detection of antrum AG. Mini-abstract: Pepsinogens testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis. IL-6 and HE-4 maybe of interest for the detection of antrum atrophic gastritis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.
- Author
-
Sinicrope, Frank A, Smyrk, Thomas C, Tougeron, David, Thibodeau, Stephen N, Singh, Shalini, Muranyi, Andrea, Shanmugam, Kandavel, Grogan, Thomas M, Alberts, Steven R, and Shi, Qian
- Abstract
Background: A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma. BRAFV600E mutations are frequently detected in tumors with microsatellite instability and indicate a sporadic origin. We used a mutation-specific antibody to examine mutant BRAFV600E protein expression and its concordance with BRAFV600E mutation data.Methods: Primary stage III colon carcinomas were analyzed for BRAFV600E mutations in exon 15, and 50 BRAFV600E mutation carriers and 25 wild-type tumors were selected for analysis of BRAF proteins by immunohistochemistry (IHC). IHC was performed in archival tissue specimens using a pan-BRAF antibody and a mutation-specific antibody against BRAFV600E proteins. Staining was scored by 2 pathologists who were blinded to clinical and mutation data.Results: Using a pan-BRAF antibody, total BRAF protein expression was observed in the tumor cell cytoplasm in 74 of 75 colon carcinomas. A mutation-specific antibody identified diffuse cytoplasmic staining of mutant BRAFV600E proteins in 49 of 74 cancers. Analysis using a polymerase chain reaction-based assay revealed that all 49 of these cancers carried BRAFV600E mutations. In contrast, BRAFV600E staining was absent in all 25 tumors that carried wild-type copies of BRAF.Conclusions: A BRAF mutation-specific (V600E) antibody detected tumors with BRAFV600E mutations and exhibited complete concordance with a DNA-based method. These results support the use of IHC as a simplified strategy to screen colorectal cancers for BRAFV600E mutations in clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
42. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.
- Author
-
Sinicrope, Frank A., Smyrk, Thomas C., Tougeron, David, Thibodeau, Stephen N., Singh, Shalini, Muranyi, Andrea, Shanmugam, Kandavel, Grogan, Thomas M., Alberts, Steven R., and Shi, Qian
- Subjects
- *
COLON cancer diagnosis , *GENETIC mutation , *IMMUNOGLOBULINS , *MICROSATELLITE repeats , *TUMORS - Abstract
BACKGROUND A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma. BRAFV600E mutations are frequently detected in tumors with microsatellite instability and indicate a sporadic origin. We used a mutation-specific antibody to examine mutant BRAFV600E protein expression and its concordance with BRAFV600E mutation data. METHODS Primary stage III colon carcinomas were analyzed for BRAFV600E mutations in exon 15, and 50 BRAFV600E mutation carriers and 25 wild-type tumors were selected for analysis of BRAF proteins by immunohistochemistry (IHC). IHC was performed in archival tissue specimens using a pan-BRAF antibody and a mutation-specific antibody against BRAFV600E proteins. Staining was scored by 2 pathologists who were blinded to clinical and mutation data. RESULTS Using a pan-BRAF antibody, total BRAF protein expression was observed in the tumor cell cytoplasm in 74 of 75 colon carcinomas. A mutation-specific antibody identified diffuse cytoplasmic staining of mutant BRAFV600E proteins in 49 of 74 cancers. Analysis using a polymerase chain reaction-based assay revealed that all 49 of these cancers carried BRAFV600E mutations. In contrast, BRAFV600E staining was absent in all 25 tumors that carried wild-type copies of BRAF. CONCLUSIONS A BRAF mutation-specific (V600E) antibody detected tumors with BRAFV600E mutations and exhibited complete concordance with a DNA-based method. These results support the use of IHC as a simplified strategy to screen colorectal cancers for BRAFV600E mutations in clinical practice. Cancer 2013;119:2765-2770. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
43. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study.
- Author
-
Tasu, Jean-Pierre, Herpe, Guillaume, Damion, Jérôme, Richer, Jean-Pierre, Debeane, Bertrand, Vionnet, Mathilde, Rouleau, Laetitia, Carretier, Michel, Ferru, Aurélie, Ingrand, Pierre, and Tougeron, David
- Abstract
Objectives: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).Six men and 11 women were included (median age 61 years, range 37–77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (
n = 6/17). Median overall survival was 31 months (95% CI; 4–undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4–25) for the 11 patients without resection or R2 resection (logrankp = 0.044).After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3–4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4–undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4–25) for the patients without resection or R2 resection (logrank p = 0.044). Materials and methods: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).Six men and 11 women were included (median age 61 years, range 37–77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4–undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4–25) for the 11 patients without resection or R2 resection (logrankp = 0.044).After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3–4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4–undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4–25) for the patients without resection or R2 resection (logrank p = 0.044). Results: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).Six men and 11 women were included (median age 61 years, range 37–77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4–undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4–25) for the 11 patients without resection or R2 resection (logrankp = 0.044).After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3–4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4–undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4–25) for the patients without resection or R2 resection (logrank p = 0.044). Conclusion: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).Six men and 11 women were included (median age 61 years, range 37–77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4–undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4–25) for the 11 patients without resection or R2 resection (logrankp = 0.044).After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3–4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4–undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4–25) for the patients without resection or R2 resection (logrank p = 0.044). Clinical relevance statement: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).Six men and 11 women were included (median age 61 years, range 37–77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4–undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4–25) for the 11 patients without resection or R2 resection (logrankp = 0.044).After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3–4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4–undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4–25) for the patients without resection or R2 resection (logrank p = 0.044). Key Points: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).Six men and 11 women were included (median age 61 years, range 37–77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4–undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4–25) for the 11 patients without resection or R2 resection (logrankp = 0.044).After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.• In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3–4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4–undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4–25) for the patients without resection or R2 resection (logrank p = 0.044). [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
44. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
- Author
-
Parisi, Alessandro, Delaunay, Blandine, Pinterpe, Giada, Hollebecque, Antoine, Blanc, Jean Frederic, Bouattour, Mohamed, Assenat, Eric, Ben Abdelghani, Meher, Sarabi, Matthieu, Niger, Monica, Vivaldi, Caterina, Mandalà, Mario, Palloni, Andrea, Bensi, Maria, Garattini, Silvio Ken, Tougeron, David, Combe, Pierre, Salati, Massimiliano, Rimini, Margherita, and Cella, Chiara Alessandra
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *DRUG efficacy , *RESEARCH , *SCIENTIFIC observation , *CHOLANGIOCARCINOMA , *METASTASIS , *CELL receptors , *RETROSPECTIVE studies , *GENE rearrangement , *DESCRIPTIVE statistics , *LONGITUDINAL method , *EVALUATION - Abstract
Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. A joint analysis of two multicentre observational retrospective cohort studies independently conducted in France and Italy was performed. All consecutive FGFR2-positive patients affected by CCA and treated with pemigatinib as second- or further line of systemic treatment in clinical practice, within or outside the European Expanded Access Program, were included. Between July 2020 and September 2022, 72 patients were treated with pemigatinib in 14 Italian and 25 French Centres. Patients had a median age of 57 years, 76% were female, 81% had ECOG-PS 0–1, 99% had intrahepatic CCA, 74% had ≥ 2 metastatic sites, 67% had metastatic disease at diagnosis, while 38.8% received ≥ 2 previous lines of systemic treatment. At data cut-off analysis (April 2023), ORR and DCR were 45.8% and 84.7%, respectively. Median DoR was 7 months (IQR: 5.8–9.3). Over a median follow-up time of 19.5 months, median PFS and 1-year PFS rate were 8.7 months and 32.8%. Median OS and 1-year OS rate were 17.1 months and 60.6%. Fatigue (69.4%), ocular toxicity (68%), nail toxicities (61.1%), dermatologic toxicity (41.6%) hyperphosphataemia (55.6%), stomatitis (48.6%), and diarrhea (36.1%) were the most frequent, mainly G1-G2 AEs. Overall incidence of G3 AEs was 22.2%, while no patient experienced G4 AE. Dose reduction and temporary discontinuation were needed in 33.3% and 40.3% of cases, with 1 permanent discontinuation due to AEs. These results confirm the effectiveness and safety of pemigatinib in a real-world setting. • Effectiveness of pemigatinib in advanced FGFR2-positive CCA patients was investigated. • ORR was 45.8%, DCR was 84.7%, median PFS was 8.7 months, median OS was 17.1 months. • Effectiveness and safety of pemigatinib was confirmed in a real-world setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
- Author
-
Saberzadeh-Ardestani, Bahar, Jones, Jeremy C., McWilliams, Robert R., Tougeron, David, Halfdanarson, Thorvardur R., Guimbaud, Rosine, Hubbard, Joleen M., Flecchia, Clémence, Shi, Qian, Alouani, Emily, Sonbol, Mohamad B., Ticku, Jonathan, Jin, Zhaohui, Taieb, Julien, and Sinicrope, Frank A.
- Subjects
- *
LIVER tumors , *IMMUNE checkpoint inhibitors , *CONFIDENCE intervals , *METASTASIS , *RETROSPECTIVE studies , *REGRESSION analysis , *COLORECTAL cancer , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *LONGITUDINAL method , *PROPORTIONAL hazards models , *IMMUNOTHERAPY - Abstract
Only one-half of deficient mismatch repair (d-MMR) metastatic colorectal cancers (mCRC) demonstrate durable responses to immune checkpoint inhibitors (ICIs). Given preclinical data indicating that liver metastases sequester activated CD8+ T cells from systemic circulation, we examined clinical outcome by metastatic site. In a retrospective cohort of patients with d-MMR mCRCs treated at multiple centers in France (n = 66), we sought to validate data from a U.S. cohort, and performed pooled analysis (n = 104). All patients received first-line ICI monotherapy. Metastatic site was analyzed in relationship to tumor response (RECIST version 1.1), and with progression-free survival (PFS) by multivariable stratified Cox regression after adjustment for covariates. Objective responses were achieved in 38/66 (58%) of patients in the validation cohort. Best tumor response included 13 (20%) complete responses (CR), 25 (38%) partial responses (PR), 16 (25%) stable disease, and 11 (17%) progressive disease (PD). One-year and 5-year PFS rates were 73% and 67%, respectively; 18 (27%) patients progressed during immunotherapy. Best tumor response was attenuated in patients with liver metastasis (P = 0.03). Presence of liver metastasis, but not other sites, was associated with significantly poorer PFS after adjustment for covariates (HR adj 2.82; 95%CI, 1.08–7.39; P adj =0.03). In a pooled analysis, liver metastasis remained significantly and independently associated with poorer PFS (HR adj 3.18; 95%CI, 1.52–6.67; P adj =0.002) and with attenuated tumor best response (P = 0.01). Metastasis to the liver, but not other sites, was validated as an independent factor associated with poorer response and survival after ICI treatment in d-MMR mCRCs. These data underscore the need for novel therapeutic strategies in these patients. ● Patients were treated with an immune checkpoint inhibitor as first-line therapy. ● An independent patient cohort and pooled analysis of d-MMR mCRCs was performed. ● Liver metastasis was associated with poorer survival after ICI. ● Other sites of disease spread were not associated with poorer survival after ICI. ● Liver metastasis was validated as associated with shorter survival after ICI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas.
- Author
-
de Monsabert, Camille Goislard, Touchefeu, Yann, Guiu, Boris, Campillo-Gimenez, Boris, Farges, Olivier, Tougeron, David, Baumgaertner, Isabelle, Ayav, Ahmet, Beuzit, Luc, Pracht, Marc, Lièvre, Astrid, Le Sourd, Samuel, Boudjema, Karim, Rolland, Yan, Garin, Etienne, Boucher, Eveline, and Edeline, Julien
- Subjects
- *
QUALITY of life , *CANCER chemotherapy , *RADIOEMBOLIZATION , *ANTINEOPLASTIC agents , *COMBINATION drug therapy - Abstract
Background: In the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) singlearm phase 2 trial, concomitant chemotherapy and selective internal radiotherapy (SIRT) showed antitumor activity as a first-line treatment of unresectable intrahepatic cholangiocarcinomas (ICCs). In this sub-analysis, we aimed to evaluate one of the secondary endpoints, the health-related quality of life (QoL), evaluated with an EORTC QLQ-C30 instrument at the baseline and during treatment. Methods: The MISPHEC trial included treatment-naïve patients with an unresectable ICC between November 2013 and June 2016. Patients received concomitant first-line chemotherapy with cisplatin and gemcitabine for 8 cycles; SIRT was administered during cycle 1 (for patients with unilobar disease) or cycles 1 and 3 (for patients with bilobar disease) using glass Yttrium-90 microspheres. We evaluated the QoL--measured by the QLQ-C30 questionnaire--at the baseline, every 8 weeks during chemotherapy and follow-up, between 12 and 15 weeks after embolization and every 12 weeks after a liver resection if applicable. Results: A total of 41 patients were included, of which 34 completed questionnaires at the baseline. No clinically significant changes in the global health score or the sub-scales of the QLQ-C30 were observed during follow-up. The physical, social and role function mean score worsened during treatment and fatigue, nausea and pain scores increased although the differences were not clinically significant. In patients undergoing subsequent surgery, the QoL was not impaired. Conclusions: A combination of SIRT and chemotherapy with gemcitabine and cisplatin as the first-line treatment of unresectable ICCs was found to maintain the QoL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells
- Author
-
Park, Jae Myung, Huang, Shengbing, Tougeron, David, and Sinicrope, Frank A.
- Subjects
- *
COLON cancer treatment , *ANTINEOPLASTIC agents , *HISTONE deacetylase inhibitors , *CANCER cells , *DNA repair , *GENE frequency , *SENSITIVITY analysis - Abstract
Background: MSH3 is a DNA mismatch repair (MMR) gene that undergoes frequent somatic mutation in colorectal cancers (CRCs) with MMR deficiency. MSH3, together with MSH2, forms the MutSβ heteroduplex that interacts with interstrand cross-links induced by drugs such as cisplatin. To date, the impact of MSH3 on chemosensitivity is unknown. Methods: We utilized isogenic HCT116 (MLH1−/MSH3−) cells where MLH1 is restored by transfer of chromosome 3 (HCT116+ch3) and also MSH3 by chromosome 5 (HCT116+3+5). We generated HCT116+3+5, SW480 (MLH1+/MSH3+) and SW48 (MLH1−/MSH3+) cells with shRNA knockdown of MSH3. Cells were treated with 5-fluorouracil (5-FU), SN-38, oxaliplatin, or the histone deacetylase (HDAC) inhibitor PCI-24781 and cell viability, clonogenic survival, DNA damage and apoptosis were analyzed. Results: MSH3-deficient vs proficient CRC cells showed increased sensitivity to the irinotecan metabolite SN-38 and to oxaliplatin, but not 5-FU, as shown in assays for apoptosis and clonogenic survival. In contrast, suppression of MLH1 attenuated the cytotoxic effect of 5-FU, but did not alter sensitivity to SN-38 or oxaliplatin. The impact of MSH3 knockdown on chemosensitivity to SN-38 and oxaliplatin was maintained independent of MLH1 status. In MSH3-deficient vs proficient cells, SN-38 and oxaliplatin induced higher levels of phosphorylated histone H2AX and Chk2, and similar results were found in MLH1-proficient SW480 cells. MSH3-deficient vs proficient cells showed increased 53BP1 nuclear foci after irradiation, suggesting that MSH3 can regulate DNA double strand break (DSB) repair. We then utilized PCI-24781 that interferes with homologous recombination (HR) indicated by a reduction in Rad51 expression. The addition of PCI-24781 to oxaliplatin enhanced cytotoxicity to a greater extent compared to either drug alone. Conclusion: MSH3 status can regulate the DNA damage response and extent of apoptosis induced by chemotherapy. The ability of MSH3 to regulate chemosensitivity was independent of MLH1 status. PCI-24781-mediated impairment of HR enhanced oxaliplatin sensitivity, suggesting that reduced DSB repair capacity may be contributory. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
48. Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer.
- Author
-
Sarafan-Vasseur, Nasrin, Sefrioui, David, Tougeron, David, Lamy, Aude, Blanchard, France, Pessot, Florence Le, Fiore, Frédéric Di, Michel, Pierre, Bézieau, Stéphane, Latouche, Jean-Baptiste, Frebourg, Thierry, and Sesboüé, Richard
- Subjects
- *
HUMAN genetic variation , *GENETIC mutation , *GENETIC polymorphisms , *COLON cancer , *CELL culture , *MESSENGER RNA - Abstract
Background: The EGFR 3' untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14) and undergoes somatic deletions in microsatellite instability (MSI) colorectal cancer (CRC). These mutations could be oncogenic in colorectal tissue since they were shown to result into increased EGFR mRNA stability in CRC cell lines. Methods: First, we determined in a case control study including 429 CRC patients corresponding to different groups selected or not on age of tumor onset and/or familial history and/or MSI, whether or not, the germline EGFR A13/A14 polymorphism constitutes a genetic risk factor for CRC; second, we investigated the frequency of somatic mutations of this repeat in 179 CRC and their impact on EGFR expression. Results: No statistically significant difference in allelic frequencies of the EGFR polyA repeat polymorphism was observed between CRC patients and controls. Somatic mutations affecting the EGFR 3'UTR polyA tract were detected in 47/80 (58.8%) MSI CRC versus 0/99 microsatellite stable (MSS) tumors. Comparative analysis in 21 CRC samples of EGFR expression, between tumor and non malignant tissues, using two independent methods showed that somatic mutations of the EGFR polyA repeat did not result into an EGFR mRNA increase. Conclusion: Germline and somatic genetic variations occurring within the EGFR 3' UTR polyA tract have no impact on CRC genetic risk and EGFR expression, respectively. Genotyping of the EGFR polyA tract has no clinical utility to identify patients with a high risk for CRC or patients who could benefit from anti-EGFR antibodies [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
49. Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome.
- Author
-
Olivier, Raphael, Randrian, Violaine, Tougeron, David, and Saurin, Jean-Christophe
- Subjects
- *
PATIENT aftercare , *PANCREATIC tumors , *STOMACH tumors , *INTESTINAL tumors , *HEREDITARY nonpolyposis colorectal cancer , *DIGESTIVE system endoscopic surgery , *EARLY detection of cancer , *MEDICAL protocols , *CANCER patients , *COLORECTAL cancer , *PATIENT compliance , *DISEASE complications - Abstract
Simple Summary: Lynch syndrome is characterized by a higher relative risk of developing certain cancers, especially digestive cancers. Many guidelines from different scientific societies are now available and allow excellent follow-up for these patients, but occasionally propose divergent management approaches. We provide here a synthesis of these guidelines and a focus on prevention, diagnosis, and endoscopic follow-up of these digestive cancers and early neoplasia. Lynch syndrome patients could benefit from various recommendations to prevent digestive cancers. In this review, we summarize the criteria to identify Lynch syndrome in patients with digestive cancers. We detail endoscopic screening procedures in patients with Lynch syndrome for gastric, small bowel, pancreatic, and colorectal cancers. We review the precise modalities of endoscopic follow-up, particularly the discrepancies that exist between the guidelines of the various scientific societies. We discuss the treatment of colorectal cancers in Lynch syndrome cases and patient adherence to endoscopic follow-up programs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies.
- Author
-
Randrian, Violaine, Evrard, Camille, and Tougeron, David
- Subjects
- *
IMMUNIZATION , *IMMUNE checkpoint inhibitors , *GENETIC mutation , *IMMUNE system , *METASTASIS , *DRUG resistance , *COLORECTAL cancer , *HUMAN microbiota , *IMMUNOLOGICAL adjuvants , *GENES , *DEGENERATION (Pathology) , *IMMUNOTHERAPY , *ANTIGENS , *THERAPEUTICS - Abstract
Simple Summary: A deficient mismatch repair system (dMMR) results in microsatellite instability (MSI). The MSI status of a tumor predicts the response to immune checkpoint inhibitors (ICI) that are now approved in patients with dMMR/MSI metastatic colorectal cancers. In addition to the mechanisms through which MSI can activate the immune system via particular neo-antigens, this review reports the clinical and pre-clinical strategies being developed in the case of resistance to ICI, including emerging therapies and new biomarkers. A defect in the DNA repair system through a deficient mismatch repair system (dMMR) leads to microsatellite instability (MSI). Microsatellites are located in both coding and non-coding sequences and dMMR/MSI tumors are associated with a high mutation burden. Some of these mutations occur in coding sequences and lead to the production of neo-antigens able to trigger an anti-tumoral immune response. This explains why non-metastatic MSI tumors are associated with high immune infiltrates and good prognosis. Metastatic MSI tumors result from tumor escape to the immune system and are associated with poor prognosis and chemoresistance. Consequently, immune checkpoint inhibitors (ICI) are highly effective and have recently been approved in dMMR/MSI metastatic colorectal cancers (mCRC). Nevertheless, some patients with dMMR/MSI mCRC have primary or secondary resistance to ICI. This review details carcinogenesis and the mechanisms through which MSI can activate the immune system. After which, we discuss mechanistic hypotheses in an attempt to explain primary and secondary resistances to ICI and emerging strategies being developed to overcome this phenomenon by targeting other immune checkpoints or through vaccination and modification of microbiota. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.